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GENERAL BACKGROUND OF PARKINSON’S DISEASE
Epidemiology
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease and one of the most common movement disorders.1,2,3 
The overall prevalence of PD is 1.4%. Prevalence increases with age; for those between 55 
and 64 years, it is 0.4%, and 4.3% for those aged above 85 years.4
According to the general practitioners’ registration system, there were almost 29,000 patients 
diagnosed with Parkinsonism, including Parkinson’s disease, in the Netherlands in 2011. 
Males are more frequently affected than females, i.e. 2.01 and 1.47 per 1000 respectively.5 
It is likely that the total number of patients with Parkinsonism in general population will 
be 2 to 2.5 times higher because of under-registration.5 Because of demographic trends in 
Western countries, the prevalence may increase at 76% for men and 44% for women till the 
year 2030, due to aging and growth of our population.5
Pathogenesis
PD is characterized by progressive loss of dopamine producing neurons in mainly the 
substantia nigra in association with the presence of Lewy bodies in surviving neurons.3,6 The 
pathology is, however, more widespread than this specific area and neural system, involving 
many areas of the brain, including the midbrain and neocortex and even other organs.7,8,9 
Despite much research as to the pathogenesis of PD, the exact cause is still unknown.1,3,10 
Different processes such as autophagy, mitochondrial and lysosomal dysfunction, 
inflammation, and protein mishandling may contribute to the disease.1,10 Although several 
causative genes have been discovered, the vast majority of the patients seem to have 
sporadic PD.1,3,11
Next to this, there are both nonmodifiable (as age and gender) and modifiable environmental 
factors (as smoking and coffee consumption) that may influence the disease process.1,11
Diagnosis
PD is a clinical diagnosis, as there are no biological markers or radiological findings during 
life that prove the diagnosis.3,8 Differentiating this hypokinetic-rigid syndrome from other 
Parkinsonian syndromes can be difficult.12 The correct diagnosis can be confirmed only 
after death by postmortem pathological research.8 According to the UK Parkinson’s Disease 
Society Brain Bank clinical diagnostic criteria, the patient should have bradykinesia and at 
least one of the following: muscular rigidity, rest tremor (4-6Hz), and/or postural instability 
not caused by primary visual, vestibular, or proprioceptive dysfunction.8 Supportive for 
the diagnosis are unilateral onset, presence of rest tremor, progressive course, persisting 
asymmetry, excellent response to levodopa treatment, severe levodopa-induced chorea, 
levodopa response for at least 5 years, and a clinical course of more than 10 years.8 
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Symptoms
Motor symptoms
Motor symptoms, which develop gradually and can manifest themselves in a wide clinical 
spectrum, are the best known symptom of PD.13,14 The cardinal symptoms are slowness and 
poverty of movement, shaking, stiffness, and postural instability.12,14 Bradykinesia is essential 
for the diagnosis and can be both distally and axially located in the PD patient.8,13 Although 
asymmetric rest tremor is the most common initial symptom, tremor can be postural 
or mixed.13,15 Where dystonia can be one of the first symptoms of PD, postural balance 
problems are more common in advanced PD. PD patients often have gait problems. Initial 
gait disorders probably represent axial bradykinesia. More advanced PD patients can have 
freezing of gait which is often associated with the loss of postural reflexes. With progression 
of the disease, patients can also develop bulbar symptoms with dysarthria, hypophonia, and 
dysphagia.13 
Non-motor symptoms
In literature, the focus has been mainly on motor symptoms and in daily practice, physicians 
fail to recognize non-motor symptoms.16-18 Non-motor symptoms, however, have gained 
considerable interest in recent years since increasing evidence demonstrates that these 
symptoms contribute to severe disability and impaired quality of life.17,18 The non-motor 
symptoms are very diverse.12,17,18 Non-motor symptoms as olfactory problems, constipation, 
depression, and rapid eye movement disorder can occur early in the disease.17 With 
progression of the disease, non-motor symptoms become more prominent and dominate 
the clinical picture.17,18 There are high rates of dementia in advanced PD, and many patients 
have cognitive impairment.17,19,20 Other mental health problems are depression, psychosis, 
anxiety, and apathy.12,16,17 Autonomic disturbances as postural hypotension, constipation, 
urological problems, hyperhidrosis, hypersalivation, and sexual dysfunction also have a 
great impact on daily living.12,17,21-23 Pain is common in PD patients.24 Pain can be the result of 
both primary (e.g. as a result of dystonia) and secondary causes (e.g. due to musculoskeletal 
problems).12,17,24 Furthermore, sleep disturbances are widely present in PD patients, as is 
fatigue.12,16,17,25,26 
Treatment
Although there are no therapies that cure PD, there are a number of available symptomatic 
treatment options.12,27-30 Most patients get medical treatment. Dopaminergic medications 
as substitute for dopamine deficiency in the brain are one of the oldest and still most 
prescribed drugs for symptomatic treatment of PD.  Levodopa is the most effective one, 
followed by dopamine receptor agonists.12,27-31 Monoamino-oxidase-B inhibitors can also be 
effective as mono therapy since it improves levels of dopamine by slowing the breakdown 
of dopamine in the brain. By adding catechol-O-methyltransferase inhibitors, on phases 
can be prolonged as it increases the level of peripheral plasmatic levodopa.12,27-30 Other 
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examples of oral medication that can reduce the severity of PD symptoms are amantadine, 
anticholinergics, beta-blockers, and clozapine.12,27,29 
In more advanced PD, there are more invasive therapeutic options. Pump therapies, e.g. 
apomorphine pump or parenteral levodopa/carbidopa intestinal gel pump provide a more 
continuous administration of drugs, which is more true to nature and therefore achieve a 
better therapeutic effect with less motor fluctuations.12,27,29,30 
In addition, neurosurgical interventions, i.e. high frequency deep brain stimulation or 
lesioning of specific brain areas can be considered when drug therapy is insufficient. Both 
the subthalamic nucleus and globus pallidus internus are the most commonly targeted 
sites.12,28,29,32-35 
All these therapeutic options can be effective in reducing motor symptoms. Treatment of 
non-motor symptoms and side effects of treatment, on the other hand, can be challenging 
and may require specific medication or nonpharmological interventions.12,27-29,34,35
Additionally, PD patients can benefit from rehabilitation, physical therapy, speech therapy, 
and occupational therapy.27,28,36-38 
Quality of life
Because of both motor and non-motor symptoms, PD is a complex disease.12 Although there 
are positive effects of medical and non-medical treatment options, these interventions can 
have side effects.35,39 All these different aspects can have influence on quality of life of PD 
patients.39-42 PD is one of the diseases having the highest impact on quality of life.43 Non-
motor symptoms, especially depression, are the greatest contributors to reduced quality of 
life, and with progression of the disease, the impact becomes more prominent.40-42
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HEALTHCARE UTILIZATION 
General
PD patients have high use of healthcare facilities, which is higher than age and sex matched 
controls.44,45 The use of a wide range of services results in a high level of direct (e.g. 
neurologists, general practitioner, (pharmaceutical) therapies, social workers, hospitalization, 
nursing home care) and indirect costs (e.g. informal care, productivity loss).46-49 In 2007,  in 
the Netherlands total healthcare costs were 74.4 billion euro, with more costs per person 
with higher age.45 Since the number of patients diagnosed with PD is expected to rise as the 
population ages, total costs will grow substantially over the next decades and the disease 
will create a considerable burden for patients and society.45,47,48
Hospitalization
General
In 2010 in the Netherlands, there were almost 1,500 hospital admissions for patients with 
Parkinsonism, including Parkinson’s disease (excluding daycare admissions), with average 
hospitalization duration of 12.6 days.51 A quarter of total healthcare costs are hospital 
related.50 Patients with Parkinsonism (including Parkinson’s disease) cost 267 million euro. 
Of Parkinsonism related costs, 8.5% was due to hospital care.51
Problems
Because of different aspects of PD, i.e. motor and non-motor symptoms, combined with co-
morbidities related to the average age of PD patients, there is a high risk of hospitalization, 
and the chances of adverse events during these admissions of this vulnerable patient group 
are considerable. 
In general, adverse events are defined as injuries that were caused by medical management, 
rather than the underlying disease, resulting in prolonged hospitalization and/or disability.52-54 
These events can result in injury varying from temporary disability to death.52,53 Most events 
cause temporary, minimal impairment.53 These events are not uncommon in hospitals, and 
they occur in about 3-17% of the hospitalizations.52,54 The most common overall adverse 
events are complications from drugs, e.g. marrow depression, bleeding, complications 
of the central nervous system, and allergic reactions.53 For patients undergoing surgery, 
wound infections are the most common type.53 However, most of the adverse events aren’t 
preventable or due to negligence care.52,53,55 Apart from the individual discomfort and distress 
adverse events cause the patient and/or family, the economic impact because of direct and 
indirect medical costs on the society is huge.56,57 For the Netherlands, the preventable direct 
medical costs are  an estimated 1% of the national healthcare budget mainly because of 
longer hospitalizations.56
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In daily practice at the outpatient clinic, many PD patients report problems during 
hospital admission. Complications, medication errors and deterioration of motor function 
are examples of these encountered problems.58-60 These issues have not been studied 
systematically. Therefore, in this thesis, the hospitalized PD patient is the point of focus.
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AIM AND OUTLINE OF THE THESIS
In the present study, we aimed to further investigate the spectrum of problems patients 
with PD encounter during these hospitalizations. We will analyze possible deterioration of 
Parkinson symptoms during hospital stay and its related risk factors to explore those aspects 
that can be changed to improve quality of care.
Therefore, in Chapter 2, we review the literature to investigate what is known about 
hospital admissions of PD patients and the extent of problems these patients have 
during their hospitalization. Also, related, possible solutions are explored. In Chapter 3, 
we retrospectively assess prevalence and risk factors of motor function deterioration in 
hospitalized PD patients. Subsequently, in Chapter 4, we explore the severity of motor 
function deterioration and its risk factors prospectively. Chapter 5 presents the results of a 
prospective study analyzing prevalence of cognitive decline in PD patients and its possible 
risk factors during hospital stay. Chapter 6 shows the results of a questionnaire examining 
if in daily practice, PD patients receive extra attention during hospital admission because 
of their vulnerability. Finally, in Chapter 7, the most important findings of this thesis are 
reflected and the directions for improvement of care and further research are outlined. 
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CHAPTER 2
clinical problems in the hospitalized 
parkinson’s disease patient: systematic review
O.H.H. Gerlach, A.Winogrodzka, W.E.J. Weber.
Movement Disorders 2011;26:197-208.
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ABSTRACT
Introduction
The clinical problems Parkinson’s disease (PD) patients encounter when admitted to a 
hospital, are known to be numerous and serious. 
Methods
These problems have been inventoried through a systematic review of literature on reasons 
for emergency and hospital admissions in PD patients, problems encountered during 
hospitalization, and possible solutions for the encountered problems using the Pubmed 
database. 
Results 
Most studies were retrospective on small numbers of patients. PD patients are hospitalized 
in frequencies ranging from 7 to 28% per year. PD/parkinsonism patients are approximately 
one and a half times more frequently and generally 2 to 14 days longer hospitalized than non-
PD patients. Acute events occurring during hospitalization were mainly urinary infection, 
confusion, and pressure ulcers. Medication errors were also frequent adverse events. 
During and after surgery PD patients had an increased incidence of infections, confusion, 
falls, and decubitus, and 31% of patients was dissatisfied in the way their PD was managed. 
There are only two studies on medication continuation during surgery and one analyzing 
the effect of an early postoperative neurologic consultation, and numerous case reports, 
and opinionated views and reviews including other substitutes for dopaminergic medication 
intraoperatively. 
Conclusions
The major clinical problems are injuries, infections, poor control of PD and complications of 
PD treatment. There are many (un-researched) proposals for improvement. A substantial 
number of PD patients’ admissions might be prevented. There should be guidelines 
concerning the hospitalized PD patients, with accent on early neurological consultation 
and team work between different specialities, and incorporating non-oral dopaminergic 
replacement therapy when necessary.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative disorder with 
a life-time risk of 2% in males and 1.3%  in females.1 Although the disorder is generally 
slowly progressive, it does have a major impact on disability and quality of life of affected 
patients.2,3 One of the lesser studied aspects of PD is the spectrum of problems PD patients 
encounter, once they are admitted to a hospital. In our own and others’ experience hospital 
admissions of PD patients are often problematic, especially so when patients are admitted 
on non-neurological wards.4,5 Problem areas are exact timing or lack of drug administration, 
administration of contra-indicated drugs, complications due to immobilization, and 
psychiatric disorders triggered by the hospital admission.6-8 As most non-neurologically 
educated health care personnel are unfamiliar with PD, protocols would be helpful to 
improve the care of PD patients in such environments.
We recently surveyed the majority of movement disorder specialist neurologists in the 
Netherlands and found that no specific guidelines or protocols exist to guide caregivers and 
PD patients in the hospital environment. Before such guidelines can be formulated, one 
needs to know the prevalence and spectrum of the problems PD patients may experience 
during their hospital stay. To this end we systemically reviewed all the existing literature on 
the problems encountered by the hospitalized PD patients. 
METHODS
We systematically reviewed the literature on reasons for emergency room (ER) and hospital 
admissions in patients with PD, problems encountered during hospitalization of this patient 
population, and possible solutions for the encountered problems, using the Pubmed 
database. Last research date was 17 June 2010. 
To identify articles we included (combinations of) keywords: See Table 1 for search details. 
Subsequently we analyzed the abstracts for relevant articles: as relevant articles we defined 
those as pertaining to the following four areas: 
1. Analysis of prevalence and reasons for ER visits and subsequent admission. 
2. Clinical problems during hospital stay. 
3. Peri- and postoperative problems.
4. Suggestions for improvement of care for the hospitalized PD patient.
We also searched the reference list of each relevant article for other applicable articles. 
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In our search there were no language limitations. We excluded articles concerning brain 
surgery.
Table 1. Pubmed search details
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Table 1. Pubmed search details 
Search Number of hits 
Parkinson* AND emergenc* 422 
Parkinson* AND hospitali*  645 
Parkinson* AND healthcare  892 
Parkinson* AND hospital admission*  45 
Parkinson* AND hospital utilization* 4  
Parkinson* AND resource use 186 
Parkinson* AND perioperative 93 
Parkinson* AND preoperative  451 
Parkinson* AND intraoperative  453 
Parkinson* AND anesthes* 373 
Parkinson* AND surgery AND cognit* 456 
Parkinson* AND surgical problems 260 
Parkinson* AND surgery AND apomorphine 289 
Parkinson* AND postoperative 1231  
Parkinson* AND surgery AND complication*  2241 
Medication interruption OR drug manipulations OR  
discontinuation OR dose reduction AND levodopa 
576 
Parkinson* AND Drug withdrawal 607 
Parkinson* AND lisuride 268 
Parkinson* AND medication error 59 
Amantadine AND intravenous*  106 
Rotigotine 247 
Parkinson* AND fracture 236 
Parkinson* AND nurse 276 
Parkinson* AND nurse specialist 26 
Parkinson* AND orthopaedic 94 
Parkinson* AND orthopedic* 52 
 
 
Subsequently we analyzed the abstracts for relevant articles: as relevant articles we defined those as 
pertaining to the following four areas:  
1. Analysis of prevalence and reasons for ER visits and subsequent admission.  
2. Clinical problems during hospital stay.  
3. Peri- and postoperative problems. 
4.  Suggestions for improvement of care for the hospitalized PD patient. 
We also searched the reference list of each relevant article for other applicable articles.  
In our search there were no language limitations. We excluded articles concerning brain surgery. 
 
 
RESULTS
Emergency room and hospital admissions
Patients with PD often need emergency treatment. There are 4 studies analyzing the reasons 
for ER admission4,9-11, including one case report11 (totalling 327 PD patients, Table 2). 16-45% 
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of PD patients visit an ER once a year.9,10,12,13 PD patients visit the ER more frequently than 
their matched reference group (0.6 versus 0.4; p=0.05).14 
We found 12 studies on hospital admissions (Table 3): 11 studies totalling 3216 PD/
parkinsonism patients4,9,10,13,15-19,21,22 and one study20 on a database with 15304 PD/
parkinsonism patients. In these studies PD patients are hospitalized in frequencies ranging 
from 7 – 28% per year.9,10,15,19,20
PD/parkinsonism patients are hospitalized approximately one and a half times more 
frequently20,23,24 and generally 2 to 14 days longer12,16,17,19,21,24-29 than non-PD patients, 
although there is not a difference in every study.15,30
Reasons for emergency and hospital admission can be divided in:
1. Direct disease related morbidity: motor complications, psychiatric symptoms, autonomic 
dysfunction, sensory symptoms, sleep disorders, and side effects of anti-parkinsonian 
drugs. 
2. Indirect disease related morbidity: traumas and pneumonia. 
3. Non-PD related causes. 
As most studies vary greatly in selection of patients, exact relative proportions of these 
3 groups cannot be assessed (Tables 2 and 3).  Some studies found that PD patients are 
more likely to be admitted to the ER and hospital for complications of the disease and its 
management than for primary motor problems.13,18 A part (5-21%) of the patients were first 
diagnosed to have PD during a hospitalization.19,21 
Table 2. Emergency room admissions
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Table 2. Emergency room admissions 
Study Inclusion Exclusion Number of 
patients  
Design Control 
group 
ER  admissions 
(%) 
Reasons ER visit 
Vargas 
20079 
PD - Hoehn &Yahr Stage 5 
- Parkinsonism 
- Severe cognitive 
dysfunction 
144 R No 22% in 1 year Primarily side effects of anti-Parkinsonian 
drugs 
Cosentino 
200510 
PD  - Parkinsonism 
- Admissions related to 
PD 
130 R No 22% in 1 year - Injuries 61%, mainly fractures 37% 
- Abdominal pain 6% 
- Pneumonia, dysphagia, dyskinesia, 
epistaxis, hearing loss, pulp disease, teeth 
extraction, lumbago, pain in joint: all 3% 
Martignoni 
20044 
PD - Parkinsonism 48 P No All selected 
patients 
- Cardiovascular 27% 
- Trauma with fractures 19% 
- Chest or abdominal problems 19% 
- Neurological (both related and unrelated 
to PD) 17% 
- Head injury 6% 
- Hip prothesis displacement 2% 
Factor 
200011 
PD  5 C No  All selected 
patients 
Severe motor off periods, dyskinesia, 
psychosis, acute confusion, panic disorder, 
pain 
Abbreviations: PD: Parkinson’s disease, ER: emergency room, R: retrospective, P: prospective, C: case report. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PD: Parkinson’s disease, ER: emergency room, R: retrospective, P: prospective, C: case report.
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Table 3. Hospital admissions
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Table 3. Hospital admissions 
Study Inclusion  Exclusion Number  Design Control 
groupa 
Hospital 
admissions  
Five most frequent admission reasons 
admission 
Vossius 
201015 
PD  108 patients P Yes  All selected 
patients 
- PD related symptoms 25% 
- Vascular disorders 14%: significant less 
than control group 
- Pulmonary disorders including 
pneumonia 12% 
- Trauma 12%: significant more than 
control group   
- Cancer 7%: significant less than control 
group 
Remark: discharge diagnosis instead of 
admission diagnosis 
Klein 
200916 
- PD 
-Emergency  
admissions to 
Neurological 
Department 
 143 patients R No All selected 
patients 
- Motor complications 37% 
- Psychosis 24% 
- Somatic problems 14% 
Guneysel 
200813 
- PD 
- Emergency 
hospital 
admission 
- Admissions 
resulting in death 
- PD diagnosis 
during ER visit 
76 patients P No All selected 
patients 
- Trauma 28% 
- UTI 20% 
- Cardiovascular 15% 
- Pneumonia, cerebrovascular both 12% 
- GI 8% 
Vargas 
20079 
PD - Hoehn &Yahr 
stage 5 
- Parkinsonism 
- Severe cognitive 
dysfunction 
144 patients R No 28%  
programmed 
admissions in 1 
year 
- Complication treatment 
- Drug adjustment 
 
Louis 
200717 
- Young-onset 
PD  
- 18-40 years 
old 
Obstetrical 
admissions 
Patients with 
diagnosis paranoia 
or schizophrenia 
714 patients R Yes  All selected 
patients 
- Psychosis 23%: significant more than 
control group 
- Craniotomy 7%: significant more than 
control group 
- Pneumonia, UTI both 6% 
- Headache or seizure 4% 
- Rehabilitation 3%: significant more than 
control group  
Remark: discharge diagnosis instead of 
admission diagnosis 
Temlett 
200618 
PD  761 hospital 
admissions 
R No All selected 
patients 
- Primary for PD 15% 
- Falls and fractures 11% 
- Pneumonia, cardiac disease both 10% 
- GI 9% 
- Organic brain syndrome 6% 
Cosentino 
200510 
 
 
 
PD  
 
 
 
 
- Parkinsonism 
- Admissions 
related to PD 
 
130 patients R No 19% in 1 year - Diseases of digestive system 17% 
- Diseases of circulatory system, 
rehabilitation both 14% 
- Cataract 10% 
- Injury, chest pain both 7% 
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- Sleep disturbance, epistaxis, abdominal 
pain, osteoarthrosis: all 3% 
Woodford 
200519 
- PD  
- Emergency 
hospital 
admission 
- Parkinsonism 
- Elective 
admissions 
- Day-case 
procedures 
- Admissions  
resulting in death of 
patient 
367 patients  R No 35% in 4 year 
 
 
- Cardiovascular 20% 
- Falls 13% 
- Pneumonia 11% 
- UTI 9% 
- Decreased mobility/ dyskinesia, 
psychiatric both 8% 
 
Guttman 
200420 
- PD 
- Use of PD 
drugs 
 
- < 25 years of age 15304 
patients 
R Yes 68% in 6 years Compared with controls: 
First: aspiration pneumonia 
Second: affective psychosis 
Third: hip fractures 
Fourth: urinary tract disorders including 
infections 
Fifth: septicemia 
Martignoni 
20044 
PD Parkinsonism 132 patients P No All selected 
patients 
Admission to neurological department: 
- Poor control of PD symptoms 37%  
- Neurological 25% 
- Diagnosis confirmation, psychiatric 
complaints both 13% 
- Sudden worsening of motor symptoms 
7%  
- Head trauma and fracture 2% 
Admission to non-neurological 
department: 
- Medical and infectious illnesses 27% 
- Traumas with fracture 24% 
- Cardio-circulatory 22% 
Tan  
199821 
PD 
 
- Drug induced 
parkinsonism  
- Parkinson-plus 
syndromes 
173 patients R No All selected 
patients 
- Chest infection 22% 
- Falls 13% 
- Control of PD symptoms 10% 
- General medical problems 9% 
- Urinary dysfunction 8% 
Kessler 
197222 
- PD 
- Paralysis 
agitans 
- Parkinsonism 
 468 patients R Yes All selected 
patients 
- PD 19% 
- Circulatory system 16% 
- Digestive system 10% 
- Accidents 9% 
- Respiratory system 8% 
- Remark: Neoplasm 4%: significant less 
than control group  
Abbreviations: PD: Parkinson’s disease, UTI: urinary tract infection, GI: gastrointestinal, R: retrospective, P: prospective. 
a Comparison with inclusion group concerning admission reasons. 
 
Abbreviations: PD: Parkinson’s disease, UTI: urinary tract infection, GI: gastrointestinal, R: retrospective, 
P: prospective.
a Comparison with inclusion group concerning admission reasons.
Problems during hospitalization 
We found one prospective study on acute events occurring during hospitalization.4 When 
admitted to a neurology ward (83 PD patients, mean age 69 years, mean disease duration 
6 years), patients received an average of 0.6 non-neurological consultations. Reasons were: 
(aspiration) pneumonia, urinary infections and retention, diarrhoea, atrial fibrillation, 
postural hypotension, low back pain, and TIA. Specialists consulted most frequently 
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were cardiologists, internal medicine specialists and orthopaedic surgeons. Acute events 
observed during hospitalization on non-neurological department of 20 patients (mean age 
80 years) after ER visits were: Urinary infection (33%), agitation, confusion and hyperthermia 
(28%), pressure ulcers and leg oedema (22%), bowel occlusion and hypotension (11%), and 
dysphagia (6%). Mortality rate during hospitalization of this last group was 20%. We found 
one retrospective study on this subject (173 PD patients), but this study is unclear on the 
presence or absence of complications before the hospital admission.21 Problems identified 
in this study do accord however with those described above.4 
Another retrospective study shows that in 74% of 35 emergency hospital admissions of PD 
patients, their medication was stopped, omitted or prescribed inappropriately with 61% 
of this group suffering significant sequelae. Non-adherence to medication schedules was 
a large problem and in 11% of cases anti-dopaminergic medication (metaclopramide) was 
prescribed.31 
In a study analyzing inpatient falls the use of anti-Parkinson’s medication was an evident risk 
factor (OR 5.04).32
Apart from the studies above we found several opinionated views and reviews on problems 
during hospitalization of PD patients. These authors point to disease fluctuations, stress7, and 
medications like butyrophenones, phenothiazines, and metoclopramide, prescribed during 
hospitalization, as possible causes of  PD exacerbation.6,33-38 Additionally, sleep disorders, 
verbal communication problems, nutritional intake difficulties, and cognitive changes are 
mentioned as problem areas.7,19,39
Perioperative problems 
We found 15 retrospective studies on problems during and after surgery in patients with PD, 
with an emphasis on the postoperative period. Of these 15, 2 retrospective studies included 
a control group of non-PD patients.25,27 One retrospective study focused on postoperative 
confusion33 and 2 retrospective studies on medication errors.40,41 Another study with 10 
patients is actually a case report with 10 PD patients,42 and the remaining 9 papers are 
retrospective studies on PD patients undergoing orthopaedic surgery.29,43-50
The first study compared 234 PD patients to a control group of 40,979, undergoing elective 
bowel resection, cholecystectomy, or radical prostatectomy, during a 6-year period. PD 
patients had a significantly increased incidence of aspiration pneumonia, urinary-tract 
infection, bacterial infections, with odds ratios of 3.8, 2.0, 1.7, respectively. Odds ratios 
for postoperative delirium and hypotension in PD patients were 2.6 and 2.5, with lesser 
significance. PD patients had a mortality rate of 7.3%, compared with a 3.8% in the control 
group.25 
In the second study with a non-PD control group, 51 PD patients, treated on different surgical 
departments, were compared using matched-pair analysis. There were significantly more 
postoperative falls in the PD group (18% vs. 4%), and a higher although not significantly 
increased number of urinary tract infections (33% vs. 24%), pneumonia (10% vs. 4%), 
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and also wound infection, urinary retention, respiratory insufficiency, and postoperative 
confusion. PD patients were hospitalized for more days and stayed on the intensive care 
unit longer.27 
Another retrospective study showed that 60% of 25 PD patients with no pre-existent mental 
status abnormalities suffered postoperative confusion, some with hallucinations. The onset 
of the delirium was often delayed, 70% after 36 hours. In this study, there was no relationship 
between delirium and type of anti-Parkinson medication or anaesthetic procedure.33 
In a retrospective study on pharmacological management during 51 surgical admissions of 
PD patients or patients with parkinsonian syndromes treated with PD medication, 71% had 
missed doses of their medication. Overall, antidopaminergic medication was prescribed 
in 41% and administrated in 22% although not allowed. 47% (69% for non-day-cases 
admissions) had complications: neuropsyciatric 41%, falls 8%, and worsening of motor 
symptoms 5%.40 A second study on pharmacological management found that 30% of 92 PD 
patients had medication administration problems, leading to an increase in postoperative 
confusion or worsening of PD:  84% to 36% in the well-managed group. Overall 31% of 
patients was dissatisfied in the way their PD was managed in the perioperative period.41
In the smallest study (n=10), all patients had complications. This paper identified the same 
problems as mentioned above, and additionally found pressure sores as an important 
problem.42
Next to the above studies, there are 9 retrospective research articles on orthopaedic surgery 
and its complications. These studies (totalling 433 PD patients, Table 4) found pneumonia, 
urinary tract infections, confusion, and decubitus as the most frequent postoperative 
complications, in frequencies up to 49%44-50 with an overall 6 month mortality up to 
47%.44,45,47,48,50,51 Apart from complications, several studies are contradictory regarding the 
outcome of orthopaedic procedures in PD patients,26,29,30,43-60 and postoperative rehabilitation 
is reported to be slower.28,55
Next to these more or less formal surveys, case report and reviews mention the following 
perioperative problems: neuroleptic malignant syndrome, medication- or anaesthetic-
induced exacerbation of PD, side-effects of PD medication, postextubation laryngeal spasm, 
bronchospasm, respiratory arrest, difficulty with salivation, gastrointestinal complications, 
deep vein thrombosis, urinary disturbances, temperature regulation problems, and tremor 
hampering eye surgery.6,8,34-38,61-80 
Improvement of care for the hospitalized PD patient
Improvement	during	hospitalization
There are no studies analyzing the effects of suggested recommendations/ improvements. 
Some authors favour a multidisciplinary approach during hospitalization.4,7 Other suggestions 
are: continuing the exact personal medication regime, education of nurses and doctors, 
being attentive for early signs of complications like pneumonia to start early treatment, 
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Table 4. Orthopedic surgery, complications
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Table 4. Orthopedic surgery, complications 
Study Inclusion Exclusion Number  Design Intervention Most frequent complications 
Mehta 
200829 
PD Total knee 
arthroplasty 
revision 
- 34 patients 
- 39 knees 
R Total knee arthroplasty - Confusion 35% 
- Superficial wound infection, 
aspiration pneumonia both 6% 
Weber 
200248 
PD - - 98 patients 
- 107 hips 
R Hip replacement - 6 Month mortality 6% 
Overall complications: 36% 
- UTI 7%  
- Dislocation 6% 
- Postoperative confusion 4%  
- Pneumonia, deep venous 
thrombosis both 3%  
Duffy 
199643 
PD - - 24 patients 
- 33 knees 
R Total knee arthroplasty - Confusion 20% 
- Deep venous thrombosis, 
superficial infections both 8%  
- Myositis ossification, urinary 
retention, wound necrosis, 
respiratory tract infection all 4% 
Turcotte 
199050 
PD  - - 87 patients 
- 94 hips 
R Hip fracture surgery After 6 months: 
- Mortality 14%: myocardial 
infarction (n=5), infection (n=2), 
pulmonary embolism (n=1), 
unknown (n=4)  
- Orthopaedic problem 14%  
- Decubitus ulcers 5% 
- Wound infections 4% 
Vince  
198946 
PD 
 
- - 9 patients 
- 13 knees 
R Total knee arthroplasty Deep vein thrombus (n=4), UTIs 
(n=3), temporary disorientation 
(n=2), skin necrosis (n=1), 
intestinal ileus (n=1), pulmonary 
embolism (n=2) 
Staeheli  
198845 
PD  Parkinsonism - 49 patients 
- 50 hips 
R Hip fracture surgery 
 
6 Months complication: 
- Mortality 20%: pneumonia 40%, 
congestive heart failure 20%, 
cerebrovascular accident 20%, 
pulmonary embolism 10%, 
cerebrovascular accident 10%, 
breast cancer 10%  
- UTI 20%, pneumonia 10%, 
decubitus ulcers 10%, pulmonary 
embolism 6%, cerebrovascular 
accident 6%, wound infection 4% 
Eventov  
198344 
- PD 
- Ambulatory 
Impacted 
subcapital 
fractures- 
- 62 patients: 45 
patients undergoing 
surgery 
R Hip fracture surgery -3 Month mortality surgery group 
31% (1 year 38%): 
bronchopneumonia 43%, 
congestive heart failure 21% 
- 3 Month mortality in patients not 
undergoing surgery 29% (35% 1 
year) 
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Abbreviation: PD: Parkinson’s disease, UTI: urinary tract infection, R: retrospective.
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Abbreviation: PD: Parkinson’s disease, UTI: urinary tract infection, R: retrospective. 
- Survivors surgery group (n=31): 
UTI 23%, decubitus 23%, 
bronchopneumonia 16%, 
contractures 6%, deep infection, 
cardiac arrythmias, myocardial 
infarction, dislocation, 
thrombophlebitis, paralytic ileus all 
3% 
- Survivors of patients not 
undergoing surgery (n=12):  
UTI 17%, decubitus 25%, 
bronchopneumonia 0%, 
contractures 17% 
Coughlin  
198047 
- PD  
- Ambulatory  
- - 47 patients 
- 49 hips 
R Hip fracture surgery - 6 Month mortality 47% 
- Decubitus 49% 
- Dislocation 37% 
(endoprosthesis) 
Rothermel 
197249 
PD - - 23 patients: 16 
without levodopa, 7 
with levodopa 
R Hip fracture surgery - With levodopa: phlebitis n=1 
- Without levodopa: debrided 
decubitus ulcers n=2, phlebitis 
n=2, deep hematoma n=2, 
dislocation n=2, urinary 
septicaemia n=1, fatal myocardial 
infarction n=1 
falling prevention, (temporary) medication adjustment, emotional support, good sleep 
hygiene by maintaining the home bedtime and trying to prevent sleeping during the day, 
sometimes consulting a sleep disorder specialist or start sleeping medication, exercise, 
speech therapy, sufficient nutritional intake high in fibre, adequate fluid intake, preventing 
a confusional state by limiting the number of care-givers and the amount of light and noise 
during night sleeping, avoiding certain medication harmful for the PD patient, and consulting 
a neurologist.7,21,31,35,37,67
Improvement	of	perioperative	care
There are only 2 studies on medication continuation during surgery81,82 and one study 
analyzing the effect of an early postoperative neurologic consultation,29 and numerous case 
reports, and opinionated views and reviews.
During preoperative screening, some authors recommend extra attention to be paid to this 
group of patients, especially to respiratory status, urologic system, fluid status, cardiovascular 
system, gastrointestinal system, autonomic system, and cognition.6,25,35,37,66,73,74,78,83 And, if 
necessary, supplemented with additional diagnostics like laboratory tests, pulmonary tests, 
electrocardiogram, and X-ray.25,66,73,78 
Most of the literature describes measures with regard to PD medication in the intraoperative 
period. To prevent large descents of dopamine levels intra- and postoperatively many 
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authors advise continuation of PD medication as long as possible preoperatively 
and resume it as soon as possible postoperatively, and PD medication is preferably 
continued.6,8,25,34,37,38,42,67-70,72-74,76,78,79,81,82,84-92 2 studies on this topic describe PD patients 
using the rotigotine transdermal patch, a non-ergot D1/D2/D3 dopamine agonist.81,82 In 
the first prospective study, oral dopaminergic medication was easily switched to rotigotine 
before surgery and resumed afterwards in 14 PD patients undergoing surgery under 
general anaesthesia. Adverse events were 2 dopaminergic side effects namely nausea and 
hallucinations and one ventricular asystole.81 The second study on this topic describes PD 
patients derived from 2 prospective clinical trails. PD patients undergoing surgery under 
general anaesthesia and who continued using rotigotine during surgery were retrospectively 
analyzed (n=25). There was no worsening of PD symptoms, but (only) 3 complications: deep 
vein thrombosis, infection and pain.82 
As other substitutes for dopaminergic medication intraoperatively, continuous intravenous 
levodopa infusion, continuous subcutaneous infusion or immediate postoperative injections 
of apomorphine, and enteral levodopa/carbidopa via nasogastric tube or duodenostomy 
have been used by various authors,68,69,72,76,78,88,92,93 but none have been studied in a controlled 
trial. The use of parenteral anticholinergic and antihistaminic medication as anti-Parkinson 
therapy is limited according to some authors, and may aggravate postoperative discomfort 
because of autonomic side-effects and confusion.72,76,78 
Some authors claim that general anaesthesia should be avoided when possible, and prefer 
local anaesthesia.37,66,67,73,75,90 This is supported by a case report of a PD patient, undergoing 
surgery with regional anaesthesia, who was successfully given levodopa and carbidopa 
orally during the operation.86 Regional anaesthesia also avoids postoperative nausea and 
vomiting.73 Less invasive interventions, like laparoscopic surgery over abdominal surgery, 
are recommended.66 Some authors advocate carefully considering the used operation 
technique.47,50 
In a retrospective study the postoperative period was analyzed in PD patients undergoing 
total knee arthroplasty receiving a preoperative or immediate postoperative neurologic 
consultation (n=13) compared with patients receiving a delayed or no visit (n=21). Only 
in the first group there was a significant improvement in total Unified Parkinson’s Disease 
Rating Scale with most improvement in activities of daily living but also an improvement 
of mood, mentation and behaviour, and motor examination. In this group there was also a 
shorter length of stay (P<0.01) and less patients were confused: 15% to 48%.29
There are many more recommendations, without formal studies. Postoperatively lung 
expansion manoeuvres, noninvasive mechanical ventilation, percussion, adequate pain 
control, aspiration precautions, (early) mobilization, recognition of unique physical limitations 
and medication combinations, physiotherapy, turning regimens, maintenance of volume 
status, antiparkinsonian therapy adjustments, analyzing urine for urinary tract infections, 
and deep venous thrombosis prophylaxis may prevent complications like pulmonary 
emboli, infections, deep vein thrombosis and decubitus.6,27,42-45,50,55,59,60,66,72,74,78,83,91,94-96 In 
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case of prolonged endotracheal intubation early tracheostomy is preferred.66 Except for 
2 case reports there is no literature concerning the pre-emptive administration of drugs 
to prevent complications. In one case report the cholinesterase inhibitor rivastigmine was 
given preoperatively to prevent delirium postoperatively in a PD patient successfully treated 
with this drug in two previous delirious episodes.97 In another case report prokinetics were 
administered in 2 patients to prevent paralytic ileus.92 Some authors suggest preventive 
antibiotics to prevent infections.44,45,59 As described before, the onset of the postoperative 
delirium is often delayed. If patients are discharged rapidly after surgery, there should 
be sufficient support in the home environment.33 Overall, team work between different 
specializations, like surgery, neurology, geriatrics, and a rehabilitation unit is generally 
advocated.28,96,98
DISCUSSION
There are few studies analyzing the problems a PD patient encounters during hospitalization, 
and there are even less studies analyzing possible solutions. Most studies are retrospective 
and have small numbers of patients. In some studies PD patients were diagnosed according 
to clear diagnostic criteria (like the United Kingdom Parkinson’s Disease Society Brain 
Bank’s clinical diagnostic criteria),4,9-11,15,19,48 but in most studies the diagnostic criteria 
were not clearly mentioned: a neurologist confirmed the diagnosis,13,43,45,46,48 or medical 
record systems and/or patients notes were used to identify PD patients,17,20-22,25,27,33,40 or 
no information according to the diagnostic criteria, except the use of PD medication, was 
given.16,31,41,42,47,49,50,81,82  
Overall PD patients are more frequently20,23,24 and longer12,16,17,19,21,24-29 hospitalized compared 
with controls. Generally the leading causes for admission are injuries (many with fractures), 
infections (mainly pneumonia and urinary tract infections (UTI)), poor control of PD and 
complications of PD treatment, psychiatric disturbances, and diseases of the circulatory 
and digestive system. A reduction of the number of admissions might be achieved by extra 
attention to fall prevention, adequate drug regulation with acuity for side effects, preventing 
and recognizing of early symptoms of infections and active monitoring in the home situation 
of both patients’ vital parameters and therapy compliance.5,18,20 When admitted to a hospital, 
most PD patients stay on a general medicine or surgery ward instead of a neurological 
one.5,15 Apart from one small prospective study4 and a retrospective study,31 little is known 
about problems occurring during hospitalization of PD patients not undergoing surgery, 
mentioning the usual direct and indirect PD related problems and medication issues.
There are more studies on complications in PD patients hospitalized for surgery, particularly 
in the postoperative period. (Aspiration) pneumonia, UTI, bacterial infections, postoperative 
falls, postoperative delirium/confusion (often with a delayed onset33), and hypotension 
occur more frequently in this group of patients than in controls.25,27 Pressure sores are also 
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an important complication.42 Mortality rates are also higher.25 These data are confirmed 
by studies on PD patients undergoing orthopaedic surgery.29,43-50 Many PD patients had 
post-operative medication administration problems with more postoperative confusion or 
worsening of PD as a result.40, 41 It is striking that almost one third of the PD patients were 
dissatisfied concerning their PD treatment.41
Suggestions	for	improvement	of	hospital	care	
There are many proposals for improvement during hospitalization in PD patients with or 
without surgery. Suggestions on improvement do vary, but most authors agree that attention 
should be given to all aspects of PD and not only to motor function. 
Most publications refer to the intraoperative period mainly to prevent a decline in dopamine 
levels because of discontinuation of dopaminergic medication, including two studies 
favouring the use of a rotigotine patch.81,82 Most authors agree that anaesthesiologists and 
surgeons should take the increased vulnerability of PD patients into account when planning 
and selecting procedures.37,47,50,66,67,73,75,86,90 One small study shows that early consultation by 
a neurologist may prevent complications and reduce length of hospital stay.29 
CONCLUSIONS 
Most studies were retrospective and had small numbers. Prospective studies with large 
numbers of PD patients, defined according to clear diagnostic criteria and preferable 
diagnosed by a specialist with special interest in PD, would be preferred for future research. 
Generally patients with PD are hospitalized much more frequently and longer than control 
groups. The leading causes are injuries, infections, poor control of PD and complications of 
PD treatment. The inclusion of hospitalization data into patient registries for PD could be a 
major improvement in identifying the important problems.
There are many (un-researched) proposals for improvement during hospitalization in PD 
patients. A substantial number of PD patients’ admissions might be prevented. There should 
be guidelines concerning the hospitalized PD patients, with accent on early neurological 
consultation or consultation of another specialist like a geriatrician with a special interest 
in PD and team work between different specialities, and on sufficient training of all people 
involved in the treatment and recovery of this patient group. This protocol should include 
dopaminergic replacement therapy in case PD patients are not allowed or able to take their 
oral medication. Preferably this therapy should not be laborious and not invasive so that it 
is easily applicable.
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ABSTRACT
Introduction 
A substantial fraction of Parkinson’s disease patients deteriorate during hospitalization, but 
the precise proportion and the reasons why have not been studied systematically and the 
focus has been on surgical wards and on Accident & Emergency departments. We assessed 
the prevalence and risk factors of deterioration of Parkinson’s disease symptoms during 
hospitalization, including all wards.
Methods
We invited Parkinson’s disease patients from 3 neurology departments in The Netherlands 
to answer a standardised questionnaire on general, disease and hospital related issues. 
Patients who had been hospitalized in the previous year were included and analyzed. 
Possible risk factors for Parkinson’s disease deterioration were identified. Proportions were 
analyzed using the Chi-Square test and a logistic regression analysis was performed. 
Results
18% of 684 Parkinson’s disease patients had been hospitalized at least once in the last 
year. 21% experienced deterioration of motor symptoms, 33% did have one or more 
complications and 26% had received incorrect anti-Parkinson’s medication. There were no 
statistically significant differences for these variables between admissions on neurologic 
or non-neurologic wards and between having surgery or not. Incorrect medication 
during hospitalization was significantly associated with higher risk (OR 5.8, CI 2.5-13.7) of 
deterioration, as were having infections (OR 6.7 CI 1.8-24.7). A higher levodopa equivalent 
dose per day was a significant risk factor for deterioration. When adjusting for different 
variables, wrong medication distribution was the most important risk factor for deterioration.
Conclusions 
Incorrect medication and infections are the important risk factors for deterioration of 
Parkinson’s disease patients both for admissions with and without surgery and both for 
admissions on neurologic and non-neurologic wards. Measures should be taken to improve 
care and incorporated in guidelines. 
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INTRODUCTION
Parkinson’s disease (PD) patients are admitted to hospitals more frequently and longer than 
the general population.1,2 Up to a quarter of the total PD patients are hospitalized each 
year.1 There is general consensus that a substantial fraction of these hospitalized PD patients 
do deteriorate, but the precise proportion and the reasons why have not been studied 
systematically and the focus has been on surgical wards and on Accident & Emergency 
departments.3-6 We found that, although many PD patients seem to deteriorate during 
hospitalization and there is concern about the quality of care provided to these patients7, 
most hospitals do not have proper guidelines yet to prevent worsening of PD symptoms 
and complications during hospitalization.8 Before such guidelines can be formulated, a 
better understanding of the problems encountered during hospitalization of this group of 
patients is warranted. Our aim in this study was to assess the prevalence and risk factors of 
deterioration in hospitalized PD patients including all wards. 
METHODS
PD patients from 3 neurology departments in the southern part of The Netherlands 
were invited to participate in the survey, i.e. the Maastricht University Medical Centre in 
Maastricht, Orbis Medical Centre in Sittard-Geleen, and Catharina Hospital Eindhoven in 
Eindhoven. Only PD patients, of whom the diagnosis had been confirmed by a neurologist 
according to the UK Brain Bank criteria were selected. All patients with other or unclear 
parkinsonisms were excluded. The selected patients were sent a questionnaire by mail. 
This questionnaire consisted of questions concerning general, personal and disease related 
issues (see additional file 1 and 2). Patients were asked whether or not having cognitive 
problems. To obtain more accurate data, we asked patients to fill in the questionnaire with 
the help of a caregiver. Patients who confirmed that they had been admitted to a hospital 
in the previous year, were asked to answer more detailed questions about this hospital 
stay (e.g. exact timing or lack of drug administration, complications, and PD deterioration). 
After 4 weeks we sent a reminder to patients who had not yet returned the questionnaire. 
We validated the data by comparing the questionnaire-replies with corresponding hospital 
records. Only patients with a hospital submission in the previous year were included and 
analyzed. Admissions for PD related brain surgery were excluded. Subsequently, we tried to 
identify possible risk factors for PD deterioration. 
PD deterioration we defined as decline in motor function. Receiving incorrect PD medication 
during the hospital stay was defined as administration of PD drugs during the hospital 
stay not as home schedule with attention to interruption, wrong timing, and different PD 
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medication. Levodopa Equivalent Dose (LED) was used to calculate the amount of anti-
parkinsonian drugs.9 
The ethics committees of the 3 collaborating hospitals approved our study: Medical Ethics 
Committee academic hospital Maastricht/Maastricht university (reference number 08-5-
082), Local Advisory Group Scientific Research Orbis Medical Centre (reference number 
10.029), and Medical Ethics Committee Catharina Hospital Eindhoven (reference number 
M11-015). Research was carried out in compliance with the Helsinki Declaration.
Statistical methods
We compared proportions using the Chi-Square test for independence and subsequently 
performed a logistic regression analysis. A P-value of less than 0.05 is considered statistically 
significant. Admissions were not included if there were data missing required for that specific 
analysis. All statistical analysis are performed with PASW-version 18.0 (SPSS, Chicago). 
RESULTS
Response rate
We invited 884 patients to participate, and data from 684 patients (response rate 77%) 
were available for this study (Table 1). In total 123 patients were admitted to hospital in the 
previous year, accounting for 159 admissions, and these were used for analysis. 60% of the 
PD patients filled in the questionnaire together with a caregiver.
Hospitalization
18% of the PD patients were hospitalized at least once in the last year with an average 
of 1.3 (ranging between 1 and 4) admissions per patient per year. Patients were admitted 
most frequently on a non-neurological ward, being surgery (24%), internal medicine (22%), 
orthopaedics (15%), urology (13%), cardiology (11%) and others. Admission reasons for 
these wards were traumatic injury whether or not following surgery (20%), urinary tract 
problems (15%), gastrointestinal problems (15%), cardiac problems (12%), other surgical 
procedures (11%), elective joint replacement due to arthrosis (7%), pneumonia (6%), and 
others.  18% of the patients were admitted to a neurological ward. Of those, 71% had PD 
related problems (45% PD medication problems, 20% deterioration of PD, 10% PD related 
screening, 5% hallucinations/confusion, 5% swallowing problems, 15% unknown). Other 
reasons for admission to a neurological ward were mainly strokes.
More than a fifth of all patients experienced deterioration of motor PD symptoms during 
their hospital stay. 44% of them showed no complete recovery after discharge. Most 
patients stated to have an overall worsening of motor function (38%) or motor skills (32%). 
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The other ones had a worsening of rigidity (12%), tremor (9%), balance problems (3%), or 
bradykinesia (3%). 
For the group of patients that were admitted because of PD deterioration, one patient 
further deteriorated during this admission. This patient didn’t receive correct PD medication. 
A third of the patients did have one or more complications during the admission, mainly 
confusion followed by infections. Complications didn’t differ between non-neurologic and 
neurologic wards (P=0.83). There was not more confusion (P=0.80) or other statistically 
significant differences in complication rates among patients whether or not having surgery. 
Of the patients having an infection as a complication during admission, none of them had 
an infection as admission reason.
More than a quarter of the patients reported receiving incorrect PD medication during the 
hospital stay, i.e. wrong timing (79%), different PD medication (29%) or interruption of PD 
medication (5%). No difference in medication distribution problems between neurologic 
and non-neurologic wards (P=0.49) or whether or not patients having surgery (P=0.07) was 
found. In 3% there was self-administration of PD drugs. 
Deterioration and relating factors
With respect to the general and PD related characteristics only for patients with a LED-
value of more than 700mg/day there is a significantly increased risk for deterioration of PD 
symptoms (Table 2). 
As to hospital related risk factors incorrect medication administration during hospitalization 
was significantly associated with deterioration during admission. This was also the case when 
one or more complications occurred. Analyzing the individual complications, only infections 
showed to be a significantly increased risk factor. No other variables were significant.
In 14% of the admissions, PD patients had both cognitive problems and didn’t have the help 
of a caregiver to fill in the questionnaire. When excluding this group of patients, since the 
reported data maybe less reliable, both medication problems during admission (P=0.00, 
odds-ratio 6.0, 95%-confidence interval 2.4-14.9) and a LED-value of more than 600mg/dag 
(P=0.024, odds-ratio 3.25, 95%-confidence interval 1.2-9.0) are significant risk factors for 
deterioration, and infections aren’t (P=0.08).
When adjusting for possible confounders (logistic regression was applied using the following 
variables: Age, gender, PD duration, LED-value, Hoehn& Yahr scale, presence of cognitive 
problems, recruitment centre, wrong medication distribution, complications, infections, 
surgery, non-neurologic ward admission, consultation of PD nurse specialist and involvement 
of paramedics), there was still a significantly increased risk of deterioration in PD patients 
who had received incorrect medication (P=0.042). 
Validation
We were able to retrieve clinical files of 84 (52%) admissions. Most of the other files got lost 
because of an intermittent change in computerized medical systems. In those files, which 
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Table 1. Patient and hospitalization characteristics 
 MUMC  OMC  CHE  Total  Homogeneityc 
Total questionnaires (n) 447  230  207  884   
Response rate (%) 72  84  81  77   
Admitted patients (n) 53  34  36  123   
Total hospitalizations (n) 61  47  51  159   
          
Age (yr) 71 [SD=10.4]  75 [SD=7.6]  71 [SD=8.5]  72 [SD=9.2]  0.87 
Disease duration (yr) 9.6 [SD=7.0]  9.1 [SD=7.2]  10.7 [SD=6.9]  9.8 [SD=7.0]  0.49 
LED-value (mg/day) 554  761  855  711  0.004 
          
 na %a na %a na %a na %a  
Gender           
Women 28 46 15 32 14 28 57 36 0.04 
Men 33 54 32 68 37 72 102 64  
Hoehn&Yahr          
stage < III 24 39 20 43 13 25 57 36 0.12 
stage III, IV 33 54 25 53 33 65 91 57 0.32 
stage V 3 5 2 4 5 10 10 6 0.33 
Don't know / missing 1 2 0 0 0 0 1 1  
On-off fluctuations          
Yes 27 44 14 30 21 41 62 39 0.61 
No 33 54 33 70 30 59 96 60  
Don’t know / missing 1 2 0 0 0 0 1 1  
Cognitive problems          
Yes 20 33 24 51 29 57 72 46 0.009 
No 41 67 23 49 22 43 86 54  
Don’t know / missing 0 0 0 0 0 0 0 0  
Deterioration during admission          
Yes 13 21 10 21 11 22 34 21 0.84 
No 45 74 30 64 35 69 110 69  
Don't know / missing 3 5 7 15 5 10 15 9  
Complications during admission          
None 40 66 30 64 35 69 105 66 0.76 
One or more complications 21 34 15 32 16 31 52 33 0.30 
Confusion 13 21 11 23 11 22 35 22 0.91 
Urinary tract infection 4 7 6 13 2 4 12 8 0.70 
Emotional disturbance 6 10 0 0 0 0 6 4 0.004 
Pneumonia 0 0 2 4 2 4 4 3 0.17 
Memory complaints 2 3 0 0 3 6 5 3 0.50 
Falls 0 0 2 4 0 0 2 1 0.87 
Other 2 3 0 0 3 6 5 3 0.50 
Don't know / missing 0 0 2 4 0 0 2 1  
Medication distribution          
Good 40 66 29 62 39 76 108 68 0.15 
Bad 18 30 16 34 8 16 42 26  
Don't know / missing 3 5 2 4 4 8 9 6  
Surgery          
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Yes 39 64 21 45 31 61 91 57 0.63 
No 22 36 26 55 20 39 68 43  
Don't know / missing 0 0 0 0 0 0 0 0  
Ward          
Neurologic 11 18 6 13 11 22 28 18 0.68 
Non-neurologic 48 79 41 87 39 76 128 81  
Don't know / missing 2 3 0 0 1 2 3 2  
Involvement of paramedics          
Yes 23 38 29 62 8 16 60 38 0.025 
No 34 56 14 30 41 80 89 56  
Don't know / missing 4 7 4 9 2 4 10 6  
Consultation of PD nurse specialistb          
Yes 14 23 20 43 5 10 39 25 0.14 
No 45 74 24 51 44 86 113 71  
Don't know / missing 2 3 3 6 2 4 7 4  
a N; number and percentage of total admissions 
b Non-neurological ward 
c For homogeneity between different centres the Pearson Correlation and Spearman’s rho tests were used. P-values are shown. 
P-value <0.05 is considered significant. 
Abbreviations: MUMC: Maastricht University Medical Centre, OMC: Orbis Medical Centre, CHE: Catharina Hospital Eindhoven, 
n: number, SD: standard deviation, LED-value: Levodopa Equivalent Dose, PD: Parkinson's disease. 
 
a N; number and percentage of total admissions
b Non-neurological ward
c For homogeneity between diff rent centres the Pearson rrelation and Spe rman’s rho tests were us d. P-values 
are shown. P-value < .05 is consi ered significant.
Abbreviations: MUMC: aastricht University Medical Centre, OMC: Orbis Medical Centre, CHE: Catharina Hospital 
Eindhoven, n: number, SD: standard deviation, LED-value: Levodopa Equivalent Dose, PD: Parkinson’s disease.
thus comprise a sample half the size of our patient sample, a doctor only once documented 
deterioration of PD. There was no report of deterioration by a nurse (vs. 34 by the patients). 
PD medication distribution problems were mentioned 7 times by a doctor and 12 times 
by a nurse (vs. 42 by the patients). Urinary tract infections were reported 8 times (vs. 12), 
confusion 13 times (vs. 35), pneumonia 3 times (vs. 4) and furthermore 3 others.
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Table 2. Effect of patient, Parkinson’s disease characteristics, and factors during 
hospitalization on deterioration of Parkinson's disease  
 Deterioration (n=34) 
Possible risk factors N P-valuea OR [95%-CI] 
Gender                               
Male 25 0.39 
 
 
Age                              
≥70 years 20 0.42 
 
 
f≥80 years 5 0.47  
≥85 years 5 0.13  
Disease duration          
≥8 years 17 0.82  
≥10 years 9 0.18  
≥12 years 8 0.36  
Hoehn&Yahr                
stage ≥II 27 0.50  
stage ≥III 27 0.07  
On-off fluctuations 16 0.38  
Cognitive problems 19 0.18  
LED-value                 
>500mg/day 15 0.60 
 
 
>600mg/day 15 0.07  
>700mg/day 15 0.003 4.4 [1.7-11.5] 
Complications ≥ 1  16 0.04 2.5 [1.1-5.6] 
Confusion 10 0.23  
Infections 7 0.00 6.7 [1.8-24.7] 
Wrong medication distribution  18 0.00 5.8 [2.5-13.7] 
Surgery 17 0.26  
Non-neurologic ward 27 0.60  
No involvement of paramedics 16 0.15  
No consultation of PD nurse specialistb 17 0.04 0.3 [0.1-0.7] 
a P-value <0.05 is considered significant  
b Non-neurological ward 
Abbreviations: N: number, OR: Odds-ratio, 95%-CI: 95%-confidence interval, LED: Levodopa equivalent dose, PD: Parkinson's 
disease. 
 
 
 
 
 
 
 
a P-value <0.05 is considered significant 
b Non-neurological ward
Abbreviations: N: number, OR: Odds-ratio, 95%-CI: 95%-confidence interval, LED: Levodopa equivalent dose, PD: 
Parkinson’s disease.
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DISCUSSION
We sought to assess the prevalence and risk factors of deterioration in hospitalized PD 
patients, as evidence suggests that a substantial proportion of PD patients actually worsen 
when admitted to a hospital.1,2 In our population of 684 PD patients almost one fifth had 
been hospitalized in the last year. Traumatic injury, infections, direct PD-related problems, 
and problems with the circulatory and digestive system were the main admission reasons, 
which accords with prior literature.1,2 As in those studies, confusion and infections were the 
most common complications during hospitalization.1
To our knowledge this is the first study systematically analyzing different risk factors for 
deterioration of PD patients both for admissions with and without surgery. 
There have been earlier studies documenting high rates of incorrect medications given to 
hospitalized PD patients, some as high as 74%. All these, on surgical wards and on Accident 
& Emergency departments, found that this was associated with deterioration, but to varying 
degrees. All these studies were retrospective, and selection of the patient sample was 
unclear.3-5 We found having surgery or not did no matter in terms of medication distribution 
problems or complications. Somewhat unexpected, neurology wards do not do better, as 
there was no statistically significant difference between different wards regarding problems 
with medication distribution, complications, and PD deterioration. 
There is one retrospective study suggesting that pre-operative or immediate post-operative 
neurological consultation of PD patients having surgery may result in higher post-operative 
improvement of total Unified Parkinson’s Disease Rating Scale with most effect on activities 
on daily living.6 In our study PD nurse specialists (as part of the movement disorder teams) 
were involved in a quarter of the admissions on a non-neurological ward. This was associated 
with a higher risk on deterioration during these admissions. This is probably reverse 
causation, since PD nurse specialists were asked to see the patient when deterioration had 
already occurred. 
Second to medication distribution problems with a 5.8 higher risk on deterioration, 
complications are significantly related to PD deterioration, with infections as mean factor 
with an increased risk of 6.7. Paramedic care did not appear to be of influence. When 
analyzing different patient and PD related factors in relation to deterioration, only a LED-
value above >700mg/day showed to be a significant risk factor. For higher age and higher 
Hoehn and Yahr scores there was a tendency towards, but not a significantly, higher risk. 
When excluding those patients who had no help with answering the questionnaire and 
had cognitive problems, only wrong medication distribution and a LED-value of more than 
600mg/dag are significant risk factors.
There are significant differences for some variables between the hospitals which can be 
expected since the Maastricht University Medical Centre is, unlike the others, an university 
hospital (with more complex PD patients and more patients with deep brain stimulation). 
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There is however no significant difference between the centres in medication distribution 
problems. 
When correcting for different variables, including those that were significant different 
between the three centres, wrong medication distribution is the most important significantly 
increased risk factor for deterioration. Comparing our data with data on medication errors 
in hospitalized patients in general, showing medication errors on average in 6 per 100 
hospitalized patients, this study supports the higher vulnerability of PD patients.10
When validating the reported data by PD patients with clinical files of the admissions there 
seems to be mainly a strong underreporting of deterioration of PD supporting the lack of 
knowledge of this problem.
Apparently much more needs to be done to prevent incorrect medication distribution and 
complications. Better education of health care professionals, both on a neurological and 
non-neurological wards, to stress the importance of correctly administrated PD drugs and to 
prevent complications might result in less deterioration. Rigid electronic medication systems 
in hospitals do not seems to support home schedules of PD medication. Self-administration 
of PD drugs by able patients could be an option. The effects of an electronic warning system 
to alert the treating team of the vulnerability of this patient group, and a multidisciplinary 
approach, with a role for the clinical pharmacist and movement disorder team, should be 
evaluated in future studies.
This study has a number of limitations. Information was asked about the previous year, 
causing possible recall bias. Medication administration was assessed through self-report, 
and patients who died during admission were obviously not included. Since it was not 
possible to uncover adverse medication prescription during the admissions this aspect was 
not taken into account. Further studies should be undertaken to shed more light on these 
aspects. Nevertheless, we believe that these limitations do not invalidate our conclusions.  
CONCLUSIONS
This is the first study systematically analyzing different risk factors for deterioration of 
hospitalized PD patients both for admissions with and without surgery. There is a high 
rate of deterioration during hospitalization of PD patients on all wards. Especially incorrect 
medication distribution, but also infections are related to this. Measures should be taken to 
improve care and should be incorporated in guidelines. 
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CHAPTER 4
motor outcomes durinG hospitalization 
in parkinson’s disease patients: 
a prospective study
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ABSTRACT
Introduction
Retrospective studies suggest that many Parkinson’s disease patients have a worsening of 
their motor status during hospitalization. We aimed to quantify this prospectively, and study 
possible contributing factors.
Methods
Over one year we included all consecutive Parkinson’s disease patients, newly admitted 
to a Dutch teaching hospital. We analyzed complications, interventions, and medication 
distribution. At inclusion and at discharge we assessed the motor status with the Unified 
Parkinson’s Disease Rating Scale Part III (UPDRS-III).
Results
48% of 46 admitted patients had complications, mainly confusion/delirium (24%) and 
infections (15%). At discharge 28% of the patients had a worse motor function with a mean 
increase of more than 5 points on the UPDRS-III. Medication errors occurred in 39%. This 
is the most important risk factor (p<0.000) for motor function deterioration, followed 
by infections during hospitalization, and not being in control of own Parkinson’s disease 
medication. 24% of patients were allowed to take control of their own Parkinson’s disease 
medication, none of these patients did deteriorate.
Conclusions 
This prospective study shows that a substantial part of hospitalized PD patients has a 
significant worse motor function at discharge mainly due to medication errors and infections. 
Quality of care could be improved by addressing preventable errors and allow patients to 
take control of their own Parkinson’s disease medication.
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INTRODUCTION
Parkinson’s disease (PD) patients are hospitalized more frequently, have longer admissions, 
and suffer more complications during hospitalization compared to control groups.1 
Retrospective studies suggest that a substantial part of admitted PD patients also have a 
worsening of their motor status during these admissions, and that this is mainly due to 
medication distribution errors and infections.2-5
These studies were all retrospective and motor status was assessed through self-report or 
from medical records. To our knowledge no data are available on the severity of motor 
function deterioration during hospitalizations. Therefore, the aim of this study was to 
analyze prospectively whether or not there is deterioration of motor function at discharge 
of hospitalized PD patients compared to admission, and if so, to assess its severity and 
related factors. 
METHODS
Participants
Over a period of one year, we invited all consecutive patients with PD, admitted to the 
Maastricht University Medical Centre in Maastricht, The Netherlands, to participate. Only 
admissions related to deep brain stimulation and daycare admissions were excluded. 
Selection 
Daily, except for some weekends, the hospital medication system was searched for 
newly registered anti-Parkinson medication and related new admissions of PD patient. 
For departments not using this system, all newly admitted patients were analyzed daily 
for having PD on the basis of medical history list, prior documentation and admission 
information. In addition, neurologists on the emergency department and on wards were 
asked to look out for admitted PD patients. When a possible participant was identified, 
this patient was examined for fulfilling the UK Brain Bank criteria for PD and if so, asked to 
participate: written informed consent was obtained.
Data collection
We collected patient data at two timepoints, i.e. day one of participation (moment 1) 
and the day before or day of discharge (moment 2). Each patient was interviewed and 
examined by the same doctor (OG or MB) at both occasions. At first visit we asked questions 
about general and disease related issues. At both timepoints we interviewed patients 
about admission related issues e.g. deterioration of PD, complications, and medication 
administration with the help of a questionnaire (see additional file 3) and hospital records. 
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If possible or necessary, this interview took place in the presence of a caregiver to provide 
any extra information. We assessed the patient’s motor function through the Unified 
Parkinson’s Disease Rating Scale Part III (UPDRS-III) at both timepoints. Hoehn and Yahr-
scores were also taken. Almost daily, we reviewed the hospital records (both from doctors 
and nurses) of the included patients for complications, interventions, and (contra-indicated) 
medication prescription and distribution. Also almost daily, the same investigating physician 
who saw the patient at moments 1 and 2, checked the admitted patient without doing 
a formal physical examination. Therefore, information about possible adverse events and 
complications during admission between measurement moments 1 and 2 were retrieved 
from patients, caregivers, and hospital records and were combined. In case of a difference 
between patient information and hospital records, the visiting doctor (OG or MB) decided 
on the basis of his experience during the almost daily visits.
We defined PD deterioration as a clinically important decline in motor function: UPDRS-
III score increase between moments 1 and 2 of at least 2.5 points, i.e. minimal clinically 
important difference. We also analyzed moderate clinically important difference, i.e. 
minimum of 5.2 points higher score on the UPDRS-III on moment 2.6 Improvement of motor 
function was defined as UPDRS-III score decrease between moments 1 and 2 of at least 2.5 
points. We were not able to assess all UPDRS-III items in all patients at both timepoints, 
as sometimes the reasons for admittance interfered with this, e.g. fractures or surgery. To 
analyze the differences in motor score between inclusion and discharge per patient only 
those items were taken into account that could have been measured on both moments for 
this patient. 
Receiving incorrect PD medication during the hospital stay was defined as any administration 
of PD drugs during hospital stay not identical to the original schedule before admission with 
attention to interruption, wrong timing, and different PD medication between moments 
1 and 2. The hospital registration system for medication distribution was compared with 
patients’ (or caregivers’) information about their home medication schedule. So, if a patient 
at home sometimes missed a dose of PD medication or wasn’t that strict with timing, this 
was not counted as an error during hospitalization. Subsequently, we tried to identify 
possible risk factors for PD deterioration.
Ethical approval
The Medical Ethics Committee of the Maastricht University Medical Centre (reference 
number 10-05-010) approved this study.  
Statistical analysis 
The Chi-Square test was used. A p-value of less than 0.05 is considered statistically significant. 
All statistical analysis are performed with PAW-version 18.0 (SPSS, Chicago). 
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RESULTS
Inclusion
From the first of December 2010 till the first of December 2011, 62 admissions met the 
selection criteria: 10 were not included since no informed consent was acquired from 
these patients or their family. Therefore, 52 admissions were included accounting for 40 
PD patients. 31 patients were admitted once, the other ones 2 (n=6) or 3 times (n=3).  For 
6 admissions there was no measurement moment 2 since this was the same day or the day 
after measurement moment 1. 
During 89% of these 46 admissions with a second measurement moment, patients were 
included within the first 24 hours of admission: Day 1 (i.e. the day of admission) 18 patients 
and day 2 23 patients. Because of some admissions during the weekend or Friday evening 
(and no researcher was available) a few patients were included later: day 3 (4 patients) or 
day 4 (1 patients).  
For admission reasons see Table 1.
Admission related characteristics 
For general, PD, and admission related characteristics see Table 2.
48% of the admitted patients had complications, mainly confusion/delirium (24%) and 
infections (15%), see also Table 1. At discharge more than a quarter of the patients had a 
worse motor function with a mean increase of more than 5 points on UPDRS-III. Of those, 
most frequent were worsening of hand movements (62%), rigidity (54%), rest tremor 
(54%), finger tapping (54%), pronation-supination hand movements (46%), and kinetic 
tremor (46%). There was an improvement of motor function in less than one quarter of the 
admissions.
PD medication errors occurred in 39% of the admissions, largely consisting of wrong timing 
and less frequently by omissions. PD medication errors, infections during hospitalization, 
and not being in control of own PD medication are the only significant risk factors for motor 
function deterioration (see table 3), with the highest association (phi coefficient) for PD 
medication errors: 0.77, 0.41 and 0.36 respectively.
When analyzing a moderate clinically important worsening of motor function, 15% 
deteriorated and medication errors were still a significant risk factor (p=0.001).
24% of patients were allowed to take control of their own PD medication, none of these 
patients did deteriorate. There were significant less medication errors, more emergency 
admissions, and more surgeries including surgeries under general anesthesia in this group. 
For all the other different variables in Table 3 there was no significant difference. 
4 patients had more than one admission and during one admission a medication error and 
during another they did not. During admissions with medication errors all these patients 
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Table 1. Admission reasons and complications
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a l  . dmis ion reasons and complications 
Medical 
specialism 
Number of 
admissions (%) 
Admission reasonsa n Complications n 
Orthopedics 11 (23.9)  Hip replacement 
Hip fracture surgery 
Lumbar stenosis surgery 
Patella fracture surgery 
Rotator cuff arthropathy surgery  
Scoliosis surgery 
3 
2 
2 
2 
1 
1 
1 
Confusion/Delirium 
Hallucinations     
Decubitus   
Anemia   
Epididymitis 
UTI   
Wound infection  
5 
3 
2 
1 
1 
1 
1 
Surgery 6 (13.0) Choledochus occlusion 
Anemia  
Aortic aneurysm surgery 
Rib fracture 
Sarcoma surgery 
3 
1 
1 
1 
1 
 
Confusion/Delirium  
Hallucinations  
Anemia  
Constipation 
Drain infection 
Hematuria  
Hypotension  
UTI  
3 
2 
1 
1 
1 
1 
1 
1 
Cardiology 6 (13.0) Cardiac asthma  
Angina pectoris  
Anemia  
Heart failure  
3 
2 
1 
1 
Confusion/Delirium  
Decubitus  
Hypoglycemia  
Phlebitis 
UTI 
1 
1 
1 
1 
1 
Internal 
medicine 
5 (10.9) Anemia  
Delirium  
Decubitus  
Eye surgery  
Erysipelas 
Gastrointestinal bleeding 
Hydronephrosis 
Urosepsis  
1 
1 
1 
1 
1 
1 
1 
1 
Hypotension 
Confusion/Delirium 
Mood disorder  
 
2 
1 
1 
Pulmonology 5 (10.9) Pneumonia 
Malignant pleural effusion 
Pneumothorax 
3 
1 
1 
Confusion/Delirium 
UTI 
1 
1 
Neurology 4 (8.7) Worsening of PD 
Delirium/confusion 
Cellulites 
Hallucinations 
Eye surgery 
Orthostatic hypotension 
2 
2 
1 
1 
1 
1 
Decubitus 
Hallucinations 
 
1 
1 
Gynecology 4 (8.7) Vaginal blood loss 
Uterus extirpation 
Diagnostic laparoscopy 
Ovary cancer 
1 
1 
1 
1 
Air under skin 
Diplopia 
Splenic rupture 
Syncope 
1 
1 
1 
1 
Urology 3 (6.5) Urosepsis 
Kidney stones 
2 
1 
Paresthesia hand 1 
Ophthalmology 2 (4.3) Cataract surgery 2 -  
Total 46 (100)    43 
 
Only admissions having a second measurement (moment 2) were included.
aSome patients had more than one admission reason.
Abbreviations: N: number, PD: Parkinson’s disease, UTI: urinary tract infection.
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Table 2. General, PD, and admission related characteristics
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Table 2. General, PD, and admission related characteristics 
Characteristics  n 
Male: % 54.3 25 
Mean age: Years (SD) 74.0 (6.3) 46 
Disease durationa: Years (SD) 8.0 (7.5) 45 
Hoehn and Yahr scale at admission: Stage (SD) 3.0 (1.1) 46 
UPDRS-III score at admission: Score (SD) of total (SD) 
UPDRS-III score at discharge: Score (SD) of total (SD) 
31.6 (12.8) of 101.7 (11.2) 
32.7 (12.7) of 103.5 (10.7) 
46 
46 
Patients with on-off periods: % 13.0 6 
LED-value7: mg/day (SD) at admission 545,8 (301,4) 46 
PD medication:  
     Levodopa: % 
     Dopamine agonist: % 
     Others: % 
     Not using PD medication: % 
     Higher LED-value at discharge: % 
     Lower LED-value at discharge: % 
 
93.5 
43.5 
8.7 
2.2 
2.2 
0 
 
43 
20 
4 
1 
1 
0 
Number of patients with non per os during admission  0 
Hospitalization: Days (SD, minimum, maximum ) 8.7 (6.0, 2, 25) 46 
Emergency admissions: % 63.0 29 
Surgery: % 
     General anesthesia: % of surgeries 
     Local anesthesia: % of surgeries 
54.3 
80.0 
20.0 
25 
20 
5 
Fall incidences: % 4.3 2 
Motor function:   
     Deteriorationb:  %, change in UPDRS-III (minimum, maximum) 
     No changec:  %, change in UPDRS-III (minimum, maximum) 
     Improvementd:  %, change in UPDRS-III (minimum, maximum) 
 
28.3, 5.5 (3, 11) 
50.0, -0.3 (-2, 1) 
21.7, -6.0 (-3, -15) 
 
13 
23 
10 
PD medication errore: % 
     Wrong timing: % of medication error 
     Some rounds not distributed: % of medication error 
     Number of doses per day too low: % of medication error 
38.6 
70.6 
58.8 
11.8 
17 
12 
10 
2 
Contraindicated medicationf:  
     Metoclopramide: n prescribed; n administrated 
     Haloperidol: n prescribed; n administrated 
  
2, 0 
1, 1 
Control of own PD medication: % 23.9 11 
Involvement of allied health services:  
     Physical therapy: % 
     Occupational therapy: % 
     Speech therapy: % 
 
45.7 
4.3 
2.2 
 
21 
2 
1 
Involvement of PD nurse specialist: % 2.2 1 
 
Only admissions having a second measurement (moment 2) were included.  
a For one patient there is an unknown disease duration. 
b Mean individual UPDRS–III difference between moments 1 and 2: Worsening of at least 2.5 points. 
c Mean individual UPDRS–III difference between moments 1 and 2: Change between -2.5 and 2.5 points.  
d Mean individual UPDRS–III difference between moments 1 and 2: Improvement of at least 2.5 points. 
Only admissions having a second measurement (moment 2) were included. 
a For one patient there is an unknown disease duration.
b Mean individual UPDRS–III differenc  b tween moments 1 and 2: Worsening of at least 2.5 points.
c Mean individual UPDRS–III difference between moments 1 and 2: Change between -2.5 and 2.5 points. 
d Mean individual UPDRS–III difference between moments 1 and 2: Improvement of at least 2.5 points.
e One patient did not have PD medication and for one patient it was unclear if there was a medication error during 
admission.
f No other dopamine antagonists, anti-emetics or atypical antipsychotics were prescribed.
Abbreviations: SD: standard deviation, LED: Levodopa Equivalent Dose, PD: Parkinson’s disease, N: number.
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deteriorated, during the others none did, with a mean individual UPDRS–III difference 
between moments 1 and 2 of 4.6 and -0.75 respectively (p=0.01). None of them had an 
infection. 
One patient had his PD medication changed on purpose during admission: Levodopa was 
increased and anticholinergic drugs were stopped (not analyzed as medication error) because 
of problems at home. This patient’s motor function improved. When excluding this patient 
and those who were not included within the first 24 hours after admission, PD medication 
errors, infections during hospitalization, and not being in control of own PD medication are 
still the only significant risk factors for motor function deterioration: p=0.000, p=0.01 and 
p=0.02 respectively. 
Patients that improved during hospitalization, had significantly more emergency admissions 
and transfer to another department during hospitalization: Since a lot of patients with an 
emergency admissions to the Maastricht University Medical Centre are initially admitted 
to a temporary ward, these two factors are correlated. Of those, 40% had an infection 
as an admission reason: Proportionally more but not significantly higher compared to 
elective admissions (p=0.06). One patient his PD medication was adjusted and improved (as 
described before).  
We found that PD patients experiencing a medication error were hospitalized longer than 
those without, respectively 9.6 and 7.9 days, but this difference was not significant (p=0.40).
7 PD patients admitted to non-neurology departments were seen by a neurologist or 
geriatrician. Once this was before motor deterioration occurred and once after, the other 5 
visits were for other neurological reasons. 
During 4 admissions the researchers notified the treatment team of a PD medication error 
since the PD patient had deteriorated. Furthermore, twice contraindicated medication was 
prescribed and therefore recommended not to give.
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Table 3. Motor function of hospitalized PD patients and related factors
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 Table 3. Motor function of hospitalized PD patients and related factors 
  Number of 
admissionsa 
Number of 
patients 
deteriorated 
p-valueb 
 
Gender 
 
Male 
Female 
25 
21 
6 
7 
0.48 
Agec 
            
<75 years 
≥75 years 
25 
21 
6 
7 
0.48 
Disease durationc,d 
                                  
<8 years 
≥8 years 
32 
13 
9 
4 
1.00 
Patient with on-off periods 
                                              
No  
Yes 
40 
6 
11 
2 
1.00 
Hoehn &Yahr at admissionc 
                                                  
Stage  <4 
Stage  ≥4 
30 
16 
8 
5 
0.74 
LED-value at admission c 
                                             
<700 mg/day 
≥700 mg/day 
31 
15 
10 
3 
1.00 
 
Admission durationc 
                                     
<10 days 
≥10 days 
32 
14 
7 
6 
0.17 
Emergency admission 
                                      
No  
Yes 
17 
29 
4 
9 
0.74 
Neurology department 
                                       
No  
Yes 
42 
4 
13 
0 
0.31 
Surgery 
               
No  
Yes 
21 
25 
8 
5 
0.18 
General anesthesia 
                                 
No  
Yes 
26 
20 
9 
4 
0.28 
Complications 
                          
No  
Yes 
24 
22 
4 
9 
0.07 
Infections during hospitalization 
                                                       
No  
Yes 
39 
7 
8 
5 
0.01 
PD medication errore 
                                   
No  
Yes 
27 
17 
0 
13 
0.000 
Not in control of own PD medicationf 
                                                               
No  
Yes 
11 
34 
0 
13 
0.02 
 
Transfer to other department 
                                                 
No  
Yes 
37 
9 
10 
3 
0.70 
Physical therapy during hospitalization 
                                                                
No  
Yes 
25 
21 
5 
8 
0.18 
Overall  46 13  
aOnly admissions having a second measurement (moment 2) were included. 
bP-value <0.05 is considered significant. The Chi-Square test was used. 
c Both higher and lower cut of points were analyzed but p-values were not significant. 
d For one patient there is an unknown disease duration. 
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD medication. 
f One patient did not have PD medication. 
Abbreviations: LED: Levodopa equivalent dose;, SD: standard deviation, PD: Parkinson’s disease. 
aOnly admissions having a second measurement (moment 2) were included.
b - l  .05 is consid red significant. The Chi-Square te t was used.
c Both higher and lower cut of points were analyzed but p-values were not significant.
d For one patient there is an unknown disease duration.
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD 
medication.
f  atient id not have PD medication.
Abbreviations: LED: Levodopa equivalent dose;, SD: standard deviation, PD: Parkinson’s disease.
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DISCUSSION
This prospective study confirms prior reports about the high number of complications and 
medication errors during hospital admission of PD patients.1-4,8 Many patients had a worse 
motor function at discharge, which is not what one expects from a hospital stay. Medication 
error was the most important significantly related risk factor for deterioration, followed 
by infections during hospitalization, and not being in control of own PD medication. For 
patients who were allowed to take control of their own Parkinson’s disease medication, 
there were significantly less medication errors and therefore these factors seem to be 
positively correlated. The role of medication errors was supported by analysis of patients 
with multiple admissions, who did not deteriorate when no medication error occurred. 
Patients that improved during admission, all had emergency admissions because of acute 
disease related reasons and this may have caused worsening of PD symptoms prior to 
admission.
We included most, but not all patients within the first 24 hours of admission. Therefore, 
moment of inclusion was used as a start point for data collection during admission including 
possible adverse events and complications. 
Since UPDRS-III observations were not blinded and could have biased the results when 
interpreting the data, we applied two different definitions of motor worsening: minimal and 
moderate clinically important difference. For both, PD medication errors during admission 
were a significant risk factor for motor deterioration. This accords with a prior retrospective 
study.3 
A limitation of our study is its modest size and we could have missed some admissions. 
This relatively small study does confirm earlier retrospective studies, and we think that the 
prospective nature might even have biased the outcome in a positive way. The differences 
might have been bigger if no interventions would have taken place and the ward doctors 
wouldn’t have noticed the researchers. We also think that these results from one hospital 
only are generalizable, as prior articles from other centres report similar problems2,4,8,10 and 
our earlier retrospective study showed no difference between this centre and two others.3
To improve quality of provided care during hospitalization early involvement of PD specialists 
seems important,9,10 with special attention for the original medication schedule of the 
patient. Infections should be prevented as much as possible and PD patients should perhaps 
be allowed to control their own medication. 
CONCLUSION
This prospective study shows that a substantial part of hospitalized PD patients has a 
significant worse motor function at discharge mainly due to medication errors and infections. 
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Quality of care could be improved by addressing preventable errors and allow patients to 
take control of their own Parkinson’s disease medication.
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CHAPTER 5
coGnitive functions in parkinson’s disease 
patients durinG hospitalization: 
a prospective study
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ABSTRACT
Introduction
Motor function deterioration of PD patients during hospitalization is now well documented. 
There is anecdotal evidence that hospitalized PD patients also have cognitive deterioration. 
We aimed to prospectively assess the prevalence of cognitive decline in patients with 
Parkinson’s disease during hospitalization. 
Methods 
During one year we included 42 PD patients admitted to the Maastricht University Medical 
Centre. Both at admittance and discharge we assessed cognitive functioning with Mini-
Mental State Exam and the Scales for Outcomes of Parkinson’s disease-Cognition. We also 
collected general and disease related information, did a neurological examination and 
recorded complications and medication errors. 
Results 
We found cognitive deterioration at discharge on both Mini-Mental State Exam (42 
admissions) and Scales for Outcomes of Parkinson’s disease-Cognition (31 admissions) in 21% 
and 29% of the cases respectively. At least half of the patients experienced complications. 
More then a quarter had delirium or an episode of confusion. This was a significant risk 
factor for overall cognitive decline during hospitalization. Parkinson’s disease medication 
errors were associated with worse test results on Mini-Mental State Exam and delirium/
episode of confusion. Patients with cognitive deterioration had an increased length of 
hospital stay.
Conclusions 
A substantial part of the hospitalized PD patients have cognitive deterioration at discharge 
associated with delirium or episode of confusion resulting in a longer length of hospitalization.
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INTRODUCTION
One of Parkinson’s disease (PD) potentially most invalidating non-motor symptoms is 
cognitive impairment.1,2,3 Mild cognitive impairment is present in about one quarter of all 
PD patients, and dementia can be diagnosed in up to 83% of PD patients with longer disease 
duration.2-5 
Recent research has now extensively documented the contra-intuitive observation of 
deterioration of PD patients as they are admitted to a hospital.6-8 They are hospitalized 
more frequently and generally for longer periods than those without PD.6,9  We found that 
up to one quarter of all hospitalized PD patients experienced a substantial deterioration 
in motor function, both through medication errors and infections.7,8 Cognitive decline is a 
generally acknowledged complication of hospital admittance of the elderly patient10,11, but 
to our knowledge, this phenomenon has never been studied specifically in hospitalized PD 
patients. Since cognitive impairment in PD patients is associated with a reduced quality 
of life and increased caregiver burden12, assessment of possible cognitive decline during 
hospitalization and analysis of possible risk factors is important.
The objective of this prospective study was to determine the prevalence of cognitive decline 
in PD patients during hospitalization and to identify possible risk factors. 
METHODS
A detailed description of the methods used in this study has been published: See Chapter 4.8
Participants
During the one year study period from December 2010 till December 2011 PD patients who 
were admitted to the Maastricht University Medical Centre in Maastricht (MUMC), The 
Netherlands, and met the United Kingdom PD Brain Bank criteria were asked to participate. 
During the inclusion period we searched almost daily for newly admitted PD patients. To 
identify these PD patients different methods were used. The hospital medication system 
was analyzed to find those patients using anti-Parkinson medication. For some departments 
all medical records of newly admitted patients were screened for having PD. Next to this, 
the neurologist on the emergency department and the consulting neurologist were asked 
to report admitted PD patients. Excluded were those patients who were admitted for deep 
brain stimulation and/or daycare admissions. All included patients provided informed 
consent prior to taking part in this study.
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Data collection
During the first contact (moment 1), as soon as possible after admission, we interviewed the 
patient and asked about general and disease related issues. Additionally we did a neurologic 
examination, and assessed the following clinimetric tests: the Unified Parkinson’s Disease 
Rating Scale Part III (UPDRS-III), a Mini-Mental State Exam (MMSE), and the Scales for 
Outcomes of Parkinson’s disease-Cognition (SCOPA-Cog). MMSE is frequently used to test 
changes of cognitive function during hospitalization.13,14 SCOPA-Cog on the other hand 
is more sensitive for cognitive deficits in patients with PD.15-18 We repeated this for each 
patient the day before or day of discharge (moment 2). During this last contact we also 
asked the patient about issues regarding the admission (e.g. complications, medication 
administration). If possible a caregiver was asked for extra information.
Almost daily we collected information from the hospital records with regard to interventions, 
complications, and medication prescription and distribution and one of us visited the patient 
to gain an overall impression of the patient.
PD medication administration during hospitalization between moment 1 and 2 was 
compared to the patient’s home medication schedule and interpreted as inappropriate in 
case of a difference with regard to interruption, timing, and different PD medication. 
Ethical approval
This study was approved by The Medical Ethics Committee of the Maastricht University 
Medical Centre (reference number 10-05-010), Maastricht, The Netherlands.
Statistical analysis
Statistical analysis was performed using the statistical package IBM SPSS Statistics version 
21. We used the Chi-Square test to analyze categorical data and the independent-Sample T 
test to compare means. P-values of less than 0.05 were considered statistically significant. 
Only those hospital admissions were analyzed that both had a measurement moment 1 and 
2. 
RESULTS
Inclusion
There were 62 admissions of PD patients during the study period. 10 of those did not 
consent and we therefore excluded them.
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MMSE measurements: 
We were unable to obtain scores from 2 patients as they were in a poor physical condition and 
thus not able to do the tests. From another 8 patients we did not obtain a score at moment 
2, because of discharge of these patients the same day or day after inclusion. So follow up 
MMSE data during admission were available from 42 admissions (31 different patients). 
Most of these (N=37, 88%) were included within the first 24 hours of hospitalization, 4 
within 48 hours and one within 72 hours.
SCOPA-Cog measurements: 
We were unable to obtain both moment 1 and 2 scores from 13 patients: 10 patients found 
this test too exhausting, 2 refused to do the test and for one patient there was no time 
left because of scheduled surgery. An additional 8 patients did not do the test at moment 
2: 6 because of rapid discharge after inclusion and two because of refusal. In total we had 
SCOPA-COG data for both moment 1 and 2 for 31 admissions (24 different patients). These 
also had MMSE measurements for both moments.
PD and hospitalization related characteristics
Table 1 gives an overview of the general characteristics of the admitted PD patients. Almost 
two-third of the patients had an emergency admission. More than half of the included 
patients did undergo surgery, mainly under general anesthesia. At least half of the patients 
experienced complications during hospitalization. About 50% of those were delirium or 
confusion and about one-third infections. In about four tenths of the admissions there were 
medication errors.
Cognition
At the group level we found an overall slight improvement on the MMSE and SCOPA-Cog 
scales at discharge compared to admission. However a substantial part of the patients had 
cognitive decline during hospitalization: more than one fifth of the patients with the MMSE 
and more than a quarter of the patients with the SCOPA-Cog respectively on average 3.1 and 
2.6 points (see Table 2). 
PD medication errors and delirium or episode of confusion during hospitalization were 
the only significant risk factors for cognitive deterioration as measured with the MMSE at 
discharge compared to inclusion (see Table 3). For the SCOPA-Cog defined cognitive decline 
during admission, delirium/episode of confusion and longer duration of hospital stay were 
significant risk factors (see Table 4). For patients with delirium/episode of confusion during 
hospitalization, PD medication error is a significant risk factor (see Table 5).
In general patients with cognitive decline at discharge compared to admission had a longer 
mean length of hospitalization. For patients with a decrease in MMSE scores: 9.3 days (SD 
6.4) compared to 8.9 days (SD 5.9), although this is not a significant difference: p=0.86. 
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Table 1. General, PD, and admission related characteristics
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l  . General, PD, and admission related characteristics 
 MMSEa  
(n=42) 
SCOPA-Coga (n=31) 
Male: % 52 58 
Mean age: Years (SD) 73.7 (6.4) 73.3 (6.4) 
Disease duration: Years (SD) 7.4 (6.8) 7.4 (7.4) 
Hoehn and Yahr scale at admission: Stage (SD) 3.0 (1.0) 2.9 (0.9) 
UPDRS-III score at admission: Score (SD) of totalb (SD) 30.0 (11.7) of 101.1 (11.5) 29.2 (10.9) of 101.8 (9.9) 
Reported memory complaints before admission: % 35.7 41.9 
Patients with on-off periods: % 11.9 9.7 
LED-value: mg/day (SD) at admission 538 (309) 554 (303) 
PD medication:  
     Levodopa: % 
     Dopamine agonist: % 
     Others: % 
     Not using PD medication: % 
     Higher LED-value at discharge: % 
     Lower LED-value at discharge: % 
 
92.9 
47.6 
9.5 
2.4 
2.4 
0 
 
90.3 
58.1 
6.5 
3.2 
3.2 
0 
Number of patients with non per os 0 0 
Hospitalization: Days (SD, minimum-maximum ) 9.0 (6.0, 2-25) 9.6 (5.7, 2-23) 
Medical specialism: % 
     Orthopedics 
     Surgery 
     Cardiology 
     Internal medicine 
     Pulmonology 
     Gynecology 
     Neurology 
     Urology 
     Ophthalmology  
 
23.8 
14.3 
14.3 
11.9 
9.5 
9.5 
7.1 
7.1 
2.4 
 
25.8 
16.1 
12.9 
12.9 
6.5 
9.7 
9.7 
6.5 
0 
Emergency admissions: % 64.3 61.3 
Surgery: % 
     General anesthesia: % of surgeries 
     Local anesthesia: % of surgeries 
57.1 
79.2 
20.8 
61.3 
73.7 
26.3 
Complications: % of all admissions 
     Delirium/episode of confusion 
     Infections 
          Urinary tract infection 
          Others: Each 
     Hallucinations 
     Decubitus 
     Hypotension 
     Others: Each 
50.0 
26.2 
16.7 
9.5 
2.4 
14.3 
7.1 
7.1 
2.4 
64,5 
35.5 
19.4 
12.9 
3.2 
18.8 
9.7 
6.5 
3.2 
Fall incidences: % 4.8 6.5 
PD medication errorc: % 
     Wrong timing: % of medication error  
     Some rounds not distributed: % of medication error 
40.0 
75.0 
56.3 
44.8 
69,2 
53.8 
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     Frequency to low: % of medication error 12.5 8.7 
Opioid receptor agonist use during hospitalization 38.1 41.9 
Contraindicated medicationd:  
     Metoclopramide: N prescribed, N administrated 
     Haloperidol: N prescribed, N administrated 
 
2, 0 
1, 1 
 
1, 0 
1, 1 
Control of own PD medication: % 23.8 19.4 
Involvement of paramedics:  
     Physical therapy 
     Occupational therapy 
     Speech therapy 
 
47.6 
4.8 
0 
 
54.8 
6.5 
0 
Involvement of PD nurse specialist: %  2.4 3.2 
a Only admissions having a second measurement (moment 2) were included.  
b Only those items of the UPDRS-III that could be measured both on moment 1 and 2 were included. 
c For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD medication. 
d No other dopamine antagonists, anti-emetics or atypical antipsychotics were prescribed.  
Abbreviations: N: number, SD: standard deviation, LED: Levodopa Equivalent Dose, PD: Parkinson’s disease. 
 
 
PD and hospitalization related characteristics 
Table 1 gives an overview of the general characteristics of the admitted PD patients. Almost two-third 
of the patients had an emergency admission. More than half of the included patients did undergo 
surgery, mainly under general anesthesia. At least half of the patients experienced complications 
during hospitalization. About 50% of those were delirium or confusion and about one-third infections. 
In about four tenths of the admissions there were medication errors. 
 
 
 
a Only admissions having a second measurement (moment 2) were included. 
b ly those items of the UPDRS-III that could be measured both on moment 1 a d 2 were included.
c F r one patient it was unclear if there was a m dicatio  error during admissio  and on  patient did ’t use PD 
medication.
d No other dopamine antagonists, anti-emetics or atypical antipsychotics were prescribed. 
Abbreviations: N: number, SD: standard deviation, LED: Levodopa Equivalent Dose, PD: Parkinson’s disease.
Table 2. MMSE and SCOPA-Cog change during admission
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Table 2. MMSE and SCOPA-Cog change during admission 
 MMSEa SCOPA-Coga 
Number 42 31 
Admission: Score (SD) of totalb (SD) 25.2 (4.7) of 29.4 (1.2) 19.9 (8.2) of 41.0 (5.5) 
Discharge: Score (SD) of totalb (SD) 25.5 (4.4) of 29.4 (1.2) 21.0 (8.8) of 41.0 (5.5) 
Mean individual difference between measurement 
moment 1 and 2: Score (SD) 
0.2 (3.1) 1.1 (3.3) 
Deterioration:  %, mea  individ al difference between 
measurement moment 1 and 2 (minimum, maximum) 
21.4, 3.1 (-1, -14) 29.0, 2.6 (-1, -6) 
No change:  %, mean individual difference between 
measurement moment 1 and 2 
45.2, 0.0 12.9, 0.0 
Improvement:  %, mean individual difference between 
measurement moment 1 and 2 (minimum, maximum) 
33.3, 2.7 (1, 8) 58.1, 3.2 (1, 8) 
a Only admissions having a second measurement (moment 2) were included.  
b In some cases not all items could be analyzed because of patient related issues.  
Abbreviations: SD: standard deviation, PD: Parkinson’s disease. 
 
 
Cognition 
At the group level we found an overall slight improvement on the MMSE and SCOPA-Cog scales at 
discharge compared to admission. However a substantial part of the patients had cognitive decline 
during hospitalization: more than one fifth of the patients with the MMSE and more than a quarter of 
the patients with the SCOPA-Cog respectively on average 3.1 and 2.6 points (see Table 2).  
PD medication errors and delirium or episode of confusion during hospitalization were the only 
significant risk factors for cognitive deterioration as measured with the MMSE at discharge compared 
to inclusion (see Table 3). For the SCOPA-Cog defined cognitive decline during admission, 
delirium/episode of confusion and longer duration of hospital stay were significant risk factors (see 
Table 4). For patients with delirium/episode of confusion during hospitalization, PD medication error is 
a significant risk factor (see Table 5). 
 
 
 
a Only admissions having a second measurement (moment 2) were included. 
b In some cases not all items could be analyzed because of patient related issues. 
Abbreviations: SD: standard deviation, PD: Parkinson’s disease.
Patients with a lower SCOPA-Cog test results compared to those who didn’t, had significant 
longer average hospitalization duration i.e. 12.9 days (SD 6.5) compared to 8.3 days (SD 
4.9): p=0.04. Patients with a delirium or episode of confusion were also admitted for longer 
periods: 10.3 to 8.6 days (p=0.43).
None of the PD patients who had been given control over their PD medication had a 
dec eased MMSE score at discharge. Although he e patients, compared to ose without 
control over their medication, had a higher average MMSE score (respectively 26.3 to 24.7), 
and a lower average UPDRS-III score, 27.5 respectively 31.2, at admission (moment 1) there 
had been no significant difference in these variables: respectively p=0.38 and p=0.40. There 
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Table 3. MMSE and related factors
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abl SE and related factors 
 Admissions (n)a Lower MMSE score 
at discharge (n) 
p-valueb 
Gender 
     Male 
     Female 
 
22 
20 
 
7 
2 
 
0.14 
Agec  
     <75 years 
     ≥75 years 
 
23 
19 
 
6 
3 
 
0.48 
Disease durationc,d 
     <8 years 
     ≥8 years 
 
31 
10 
 
5 
4 
 
0.19 
Reported memory complaints before admission 
     No 
     Yes 
 
27 
15 
 
5 
4 
 
0.70 
Patient with on-off periods 
     No 
     Yes 
 
37 
5 
 
8 
1 
 
1.00 
MMSEc  < 25 at admission 
     No 
     Yes 
 
29 
13 
 
5 
4 
 
0.42 
Hoehn &Yahr at admissionc 
     stage  <4 
     stage  ≥4 
 
28 
14 
 
5 
4 
 
0.45 
LED-value at admissionc 
     <700 mg/day 
     ≥700 mg/day 
 
28 
14 
 
8 
1 
 
0.23 
Admission durationc 
     <10 days 
     ≥10 days 
 
29 
13 
 
6 
3 
 
1.00 
Emergency admission 
     No 
     Yes 
 
15 
27 
 
4 
5 
 
0.70 
Neurology department 
     No 
     Yes 
 
39 
3 
 
8 
1 
 
0.53 
Surgery 
     No 
     Yes 
 
18 
24 
 
3 
6 
 
0.71 
General anesthesia 
     No 
     Yes 
 
23 
19 
 
6 
3 
 
0.48 
Complications 
     No 
     Yes 
 
21 
21 
 
2 
7 
 
0.13 
Infections during hospitalization 
     No 
     Yes 
 
35 
7 
 
8 
1 
 
1.00 
Delirium/episode of confusion during admission    
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were less medication errors in this group (p=0.003), but no other significant differences for 
the variables in table 4. One patient in control of his PD medication had SCOPA-Cog tested 
at moment 1 and 2 and had a cognitive decline of one point.
Of the 9 patients with a decreased SCOPA-Cog score at discharge, just 4 also had a decrease 
in MMSE score. The other 5 patients with a decrease of the SCOPA-Cog test results, MMSE 
did not change (comparing moment 1 and 2).  When comparing those patients with both 
worsening of MMSE and SCOPA-Cog (N=4) to those not having any worsening on one of the 
tests (N=18), delirium or episode of confusion during hospitalization was the only significant 
risk factor for worsening of cognition at discharge compared to admission (p=0.01). These 
deteriorating patients were also admitted for a longer period, but this was not statistically 
significant 14.3 compared to 8.8 days (p=0.09).
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     No 
     Yes 
31 
11 
3 
6 
0.005 
PD medication errore 
     No 
     Yes 
 
24 
16 
 
1 
7 
 
0.004 
Opioid receptor agonist use during hospitalization 
     No 
     Yes 
 
26 
16 
 
4 
5 
 
0.27 
Not in control of own PD medicationf 
     No 
     Yes 
 
10 
31 
 
0 
9 
 
0.08 
Transfer to other department 
     No 
     Yes 
 
34 
8 
 
8 
1 
 
0.66 
Physical therapy during hospitalization 
     No 
     Yes 
 
22 
20 
 
4 
5 
 
0.71 
Overall 42 9  
a Only admissions having a second measurement were included.  
b P-value <0.05 is considered significant. 
c Both higher and lower cut of points were analyzed but p-values were not significant. 
d For one patient there is an unknown disease duration. As such, 41 patients were included. 
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD medication. 
f One patient didn’t use PD medication. 
Chi-Square test was used. 
Abbreviations: N: number, LED: Levodopa equivalent dose, PD: Parkinson’s disease. 
 
 
In general patients with cognitive decline at discharge compared to admission had a longer mean 
length of hospitalization. For patients with a decrease in MMSE ores: 9.3 days (SD 6.4) compa d to 
8.9 days (SD 5.9), although this is not a significant difference: p=0.86. Patients with a lower SCOPA-
Cog test results compared to those who didn’t, had significant longer average hospitalization duration 
i.e. 12.9 days (SD 6.5) c mpared to 8.3 days (SD 4.9): p=0.04. P tients with  delirium or episode of 
confusion were also admitted for longer periods: 10.3 to 8.6 days (p=0.43). 
None of the PD patients who had been given control over their PD medication had a decreased 
MMSE score at discharge. Although these patients, compared to those without control over their 
medication, had a higher average MMSE score (respectively 26.3 to 24.7), and a lower average 
UPDRS-III score, 27.5 respectively 31.2, at admission (moment 1) there had been no significant 
difference in these variables: respectively p=0.38 and p=0.40. There were less medication errors in 
a Only admissions having a second measurement were included. 
b - l  .05 is consid red significant.
c Both higher and lower cut of points were analyzed but p-values were not significant.
d For one patient there is an unknown disease duration. As such, 41 patients were included.
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD 
medication.
f e atient idn’t use PD medication.
Chi-Square test was used.
Abbreviations: N: number, LED: Levodopa equivalent dose, PD: Parkinson’s disease.
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Table 4. SCOPA-Cog and related factors
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a l  -   factors 
 Admissions (n)a Lower SCOPA-Cog 
score at discharge (n) 
p-valueb  
Gender 
     Male 
     Female 
 
18 
13 
 
7 
2 
 
0.24 
Agec  
     <75 years 
     ≥75 years 
 
19 
12 
 
7 
2 
 
0.42 
Disease durationc,d 
     <8 years 
     ≥8 years 
 
23 
7 
 
6 
3 
 
0.64 
Reported memory complaints before admission      
     No 
     Yes 
 
18 
13 
 
6 
3 
 
0.70 
Patient with on-off periods 
     No 
     Yes 
 
28 
3 
 
7 
2 
 
0.20 
SCOPA-Cog< 20 at admissionc 
     No 
     Yes 
 
17 
14 
 
4 
7 
 
0.15 
Hoehn &Yahr at admissionc 
    stage  <4 
    stage  ≥4 
 
22 
9 
 
4 
5 
 
0.08 
LED-value at admissionc 
     <700 mg/day 
     ≥700 mg/day 
 
20 
11 
 
7 
2 
 
0.43 
Admission durationc 
     <10 days 
     ≥10 days 
 
20 
11 
 
3 
6 
 
0.04 
Emergency admission 
     No 
     Yes 
 
12 
19 
 
5 
4 
 
0.20 
Neurology department 
     No 
     Yes 
 
28 
3 
 
8 
1 
 
1.00 
Surgery 
     No 
     Yes 
 
12 
19 
 
3 
6 
 
1.00 
General anesthesia 
     No 
     Yes 
 
17 
14 
 
6 
3 
 
0.46 
Complications 
     No 
     Yes 
 
11 
20 
 
1 
8 
 
0.11 
Infections during hospitalization 
     No 
     Yes 
 
25 
6 
 
6 
3 
 
0.32 
Delirium/episode of confusion during admission    
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     No 
     Yes 
20 
11 
2 
7 
0.003 
PD medication errore 
     No 
     Yes 
 
16 
13 
 
2 
6 
 
0.09 
Opioid receptor agonist use during hospitalization 
     No 
     Yes 
 
18 
13 
 
4 
5 
 
0.43 
Not in control of own PD medicationf 
     No 
     Yes 
 
6 
24 
 
1 
8 
 
0.64 
Transfer to other department 
     No 
     Yes 
 
26 
5 
 
7 
2 
 
0.61 
Physical therapy during hospitalization 
     No 
     Yes 
 
14 
17 
 
2 
7 
 
0.13 
Overall 31 9  
a Only admissions having a second measurement were included.  
b P-value <0.05 is considered significant. 
c Both higher and lower cut of points were analyzed but p-values were not significant. 
d For one patient there is an unknown disease duration. As such, 41 patients were included. 
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD medication. 
f One patient didn’t use PD medication. 
Chi-Square test was used. 
Abbreviations: N: number, LED: Levodopa equivalent dose, PD: Parkinson’s disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Only admissions having a second measurement were included. 
b l  0.05 is consid red significant.
c Both higher and lower cut of points were analyzed but p-values were not significant.
d For one patient there is an unknown disease duration. As such, 41 patients were included.
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD 
medication.
f  atient idn’t use PD medication.
Chi-Square test was used.
Abbreviations: N: number, LED: Levodopa equivalent dose, PD: Parkinson’s disease.
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Table 5. Delirium/confusion during hospitalization and related factors
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Table 5.  Delirium/ o f i  i  italization and related factors 
 Admissions (n)a Delirium/confusion during 
hospitalization (n) 
p-valueb  
Gender 
     Male 
     Female 
 
22 
20 
 
8 
3 
 
0.116 
Agec 
     <75 years 
     ≥75 years 
 
23 
19 
 
7 
4 
 
0.73 
Disease durationc,d 
     <8 years 
     ≥8 years 
 
31 
10 
 
6 
5 
 
0.10 
Reported memory complaints before admission 
     No 
     Yes 
 
27 
15 
 
8 
3 
 
0.72 
Patient with on-off periods 
     No 
     Yes 
 
37 
5 
 
9 
2 
 
0.59 
MMSEc < 25 at admission 
     No 
     Yes 
 
29 
13 
 
7 
4 
 
0.71 
Hoehn &Yahr at admissionc 
    stage  <4 
    stage  ≥4 
 
28 
14 
 
8 
3 
 
0.72 
LED-value at admissionc 
     <700 mg/day 
     ≥700 mg/day 
 
28 
14 
 
9 
2 
 
0.28 
Admission durationc 
     <10 days 
     ≥10 days 
 
29 
13 
 
7 
4 
 
0.71 
Emergency admission 
     No 
     Yes 
 
15 
27 
 
6 
5 
 
0.16 
Neurology department 
     No 
     Yes 
 
39 
3 
 
11 
0  
 
0.55 
Surgery 
     No 
     Yes 
 
18 
24 
 
2 
9 
 
0.08 
General anesthesia 
     No 
     Yes 
 
23 
19 
 
5 
6 
 
0.50 
Infections during hospitalization 
     No 
     Yes 
 
35 
7 
 
8 
3 
 
0.35 
PD medication errore 
     No 
     Yes 
 
24 
16 
 
2 
8 
 
0.007 
Opioid receptor agonist use during hospitalization    
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     No 
     Yes 
26 
16 
4 
7 
0.07 
Not in control of own PD medicationf 
     No 
     Yes 
 
10 
31 
 
1 
10 
 
0.24 
Physical therapy during hospitalization 
     No 
     Yes 
 
22 
20 
 
4 
7 
 
0.22 
Overall 42 11  
 a Only admissions having a second MMSE measurement were included.  
 b P-value <0.05 is considered significant. 
c Both higher and lower cut of points were analyzed but p-values were not significant. 
d For one patient there is an unknown disease duration. As such, 41 patients were included. 
e For one patient it was unclear if there was a medication error during admission and one patient didn’t use PD medication. 
f One patient didn’t use PD medication. 
Chi-Square test was used. 
Abbreviations: N, number; LED, Levodopa equivalent dose; PD, Parkinson’s disease. 
 
 
Discussion 
 
We had previously reported that a substantial part of PD patients have motor function deterioration 
during hospitalization.7,8 We have now made similar observations for cognitive functioning as well. We 
documented this prospectively with both MMSE and SCOPA-COG assessments in 42 PD patients 
admitted to a general hospital for varying reasons. Cognitive deterioration was more pronounced when 
measured with the SCOPA-Cog (29%) than with the MMSE (21%), although we were not able to take 
both test in all patients.  
Our study has limitations. The study population is small, so the results should be interpreted 
cautiously. There are also some inherent possible biases in neuropsychological testing of hospitalized 
patients. Fatigue and physical condition might have impacted performance negatively. A substantial 
portion of PD patients found the SCOPA-Cog too exhausting and did thus not complete both tests. 
MMSE, on the other hand, may not be sensitive enough to detect mild (changes in) cognitive 
impairments.13-18 As the interval between the two tests was relatively small, there could have been a 
learning effect influencing the cognitive evaluations. We were also not able to definitively rule out 
delirium or episodic confusion at the time of the tests: since this was an observational study trying not 
 a Only admissions having a second MMSE measurement were included. 
 b P-value <0.05 is considered significant.
c Both higher and lower cut of points were analyzed but p-values were not significant.
d For one pati t there is an u known di ase duration. As such, 41 patients were included.
e For one ti t it was unclear if there was a medication error during admission and one patient di n’t use PD 
medication.
f One patient didn’t use PD medication.
Chi-Square test was used.
Abbreviations: N, number; LED, Levodopa equivalent dose; PD, Parkinson’s disease.
DISCUSSION
We had previously reported that a substantial part of PD patients have motor function 
deterioration during hospitalization.7,8 We have now made similar observations for cognitive 
functioning as well. We documented this prospectively with both MMSE and SCOPA-COG 
assessments in 42 PD patients admitted to a general hospital for varying reasons. Cognitive 
deterioration was more pronounced when measured with the SCOPA-Cog (29%) than with 
the MMSE (21%), although we were not able to take both test in all patients. 
Our study has limitations. The study population is small, so the results should be interpreted 
cautiously. There are also some inherent possible biases in neuropsychological testing of 
hospitalized patients. Fatigue and physical condition might have impacted performance 
negatively. A substantial portion of PD patients found the SCOPA-Cog too exhausting and 
did thus not complete both tests. MMSE, on the other hand, may not be sensitive enough 
to detect mild (changes in) cognitive impairments.13-18 As the interval between the two 
tests was relatively small, there could have been a learning effect influencing the cognitive 
evaluations. We were also not able to definitively rule out delirium or episodic confusion 
at the time of the tests: since this was an observational study trying not to influence daily 
practice, we had not asked the treating physicians explicitly to do tests for delirium. Finally, 
pre-existi g neuropsychological impairm nts might also have affected our study, but, since 
most patients had never been tested, we do not have data on this. 
This is however the first prospective study with 2 different validated neuropsychological tests 
taken at two different time points during hospitalization, and it shows that an important 
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portion of hospitalized PD patients experiences cognitive deterioration. This study supports, 
as shown in previous studies, the high rate of delirium during hospitalization and related 
increased length of hospital stay and therefore does confirm that this is an important clinical 
problem.11,19,20 However, since the included PD patients were not compared with patients 
without PD we are not able to conclude that PD patients are more vulnarable for cognitive 
deterioration during hospitalization then patients without PD.
There are a number of possible causes and risk factors for the cognitive worsening that 
we found in our study. Delirium or episode of confusion during hospitalization was a 
significant risk factor for a worse test result on both the MMSE and SCOPA-Cog at the end 
of hospitalization. This agrees with previous reports that delirium can have a prolonged 
effect and symptoms can persist after discharge.10,11,19,20 PD medication errors during 
hospitalization are frequent and we found they were also a significant risk factor for 
cognitive decline as measured with the MMSE. Duration of the admission was a risk factor 
for cognitive deterioration as measured with the SCOPA-Cog. In general, patients worsening 
on the MMSE (not significant) and SCOPA-Cog (significant) had longer mean length of 
hospitalization. There may be a causative relation between the two, but the direction of this 
relation might work both ways.
The same holds true for delirium and medication errors. Medication errors during 
hospitalization are an important risk factor for PD patients to develop delirium or confusion. 
On the other hand PD medication errors could also be the result of cognitive impairment, 
although our overall impression during the almost daily visits was that the latter was less 
important.
Interventions to prevent delirium in hospitalized PD patients are important, but evidence 
for their effects are scarce.21 Based on our study we think an important area of possible 
improvement is medication errors. Preventing PD medication errors could be an important 
step in preventing worsening of cognitive function during hospitalization for PD patients, 
including associated delirium. We found that none of the patients who continued to take 
their medication themselves had worse MMSE final test results. This could be due to 
confounding, but we feel that there is enough evidence here to justify a randomized trial 
studying the effect of autonomous medication scheduling by the hospitalized PD patient. 
CONCLUSION
The main finding of this study is that there is a substantial part of the hospitalized PD 
patients that have cognitive deterioration at discharge mainly caused by delirium or episode 
of confusion during hospitalization resulting in a longer mean length of hospitalization. 
Measurements should be taken to prevent delirium and since PD medication errors seem to 
play an important role this should be prevented.
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CHAPTER 6
parkinson’s disease and hospitalization: 
the need for Guidelines
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ABSTRACT
Introduction
During hospitalization Parkinson patients have a higher morbidity and mortality, and a 
longer hospital stay compared with controls. We analyzed whether or not hospitalized PD 
patients are cared for with extra attention and if there are guidelines that are generally used 
in daily practice.
Methods
A questionnaire was sent to all hospitals in the Netherlands, addressed to a neurologist 
with special expertise on movement disorders or, if not present, a random neurologist was 
chosen. Questions were related to general hospital related aspects, care by a neurologist 
during the hospitalization of PD patients, and perioperative care. 
Results 
A total of 94 questionnaires were sent with a response rate of 60%. In only 2 hospitals 
the neurologist is consulted for every admitted Parkinson’s disease patient. In the other 
clinics Parkinson’s patients are mainly visited on specific request of treating physician or 
of the hospitalized patient. In 75% of the hospitals there is no system to trace admitted 
patients. In 11% of the hospitals the movement disorder specialist is involved during the 
perioperative period of a PD patient, otherwise only on request when the treating specialist 
expects complications or when complications have already occurred. In just 2 hospitals is a 
protocol available with regard to the perioperative period. In 75% of the hospitals is a PD 
nurse specialists present. In 48% of these hospitals, they are not involved in the treatment 
during the hospitalization of PD patients. 
Conclusions
In many hospitals during hospitalization PD patients are not cared for with extra attention 
by a movement disorder team. To provide the necessary extra care for every hospitalized PD 
patients a written multidisciplinary protocol could be useful. 
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INTRODUCTION
Parkinson’s disease (PD) patients are vulnerable because of both motor and non-motor 
symptoms and age related comorbidity.1-3 During hospitalization Parkinson patients have a 
higher morbidity and mortality, and a longer hospital stay, compared with controls.4,5 One 
of the key problems seems to be the lack of adherence to precise medication schedules 
and lack of knowledge as to anti-Parkinson drugs and their interactions.5-8 Standard 
consultation by a neurologist may improve the care for these patients.9 Guidelines could 
help to improve delivered care. It is however unclear if PD patients receive extra attention 
during hospitalization.
In this chapter we therefore analyzed whether PD patients are cared for with extra attention 
when they are admitted into a hospital, and if there were guidelines present that are 
generally used in daily practice.
METHODS
We mailed a questionnaire to all hospitals in the Netherlands (see additional file 4). This 
questionnaire was addressed to a neurologist with special expertise on movement disorders 
or, when there was no neurologist with this area of interest, a random neurologist was 
chosen. The neurologist was asked to return the questionnaire or answer the questions 
on the Internet. After a few weeks a reminder was sent to those that didn’t respond. 
Questions were about general aspects related to the hospital and neurology department, 
the involvement of neurology during the hospitalization of PD patients for a specialty other 
than neurology, and perioperative care. The statistical analyses are performed with PASW-
version 18.0 (SPSS, Chicago).  
RESULTS
Response rate
A total of 94 questionnaires were sent. The response rate was 60%: 5 out of 8 (63%) 
for university hospitals and 51 out of 86 (59%) for non-university hospitals. Half of the 
responders were neurologists with special expertise on movement disorders. 
Neurology department
There were on average 6.9 neurologists per hospital (full-time equivalent 2.5 till 15). Total 
number of known PD patients per hospital did vary from 10 till more than 500. 
84 PARKINSON’S DISEASE AND HOSPITALIZATION: THE NEED FOR GUIDELINES
There is a Parkinson’s disease nurse specialist available in 75% of the clinics (n=42).
Hospital related PD care
General
In 2 hospitals there is neurological consultation for every admitted Parkinson’s disease 
patient. In the other clinics Parkinson’s patients are mainly visited on specific request of the 
treating specialist (86%) and/or on specific request of the hospitalized patient (18%). 
In 75% of the hospitals there was no system to trace admitted Parkinson’s disease patients 
by the movement disorder specialist. In most other hospitals PD patients are asked to 
inform the treating doctor to consult neurology when hospitalized. No neurologist reports 
an automated warning system to alert the movement disorder team that a new PD patient 
is hospitalized.
In 64% of the hospitals there is no medication list available that shows interaction between 
different types of medication with PD medication. 
Perioperative	care
In 11% of the hospitals (all non-university ones) the movement disorder specialist is involved 
during every surgery of a PD patient, otherwise only on request when the treating specialist 
expects complications or when complications have already occurred. In half of the clinics 
no parenteral dopaminergic medication is used perioperatively. In just 2 hospitals there is 
a protocol available with regard to the perioperative period. This concerns advice about 
medication. 
For both perioperative and postoperative complications most frequent ones seen by the 
movement disorder specialist are delirium, followed by motor problems, and other cognitive 
problems. 
PD nurse specialist
PD nurse specialists are not involved during the hospitalization of patients with PD in 48% 
of the hospitals that have a PD nurse specialist. Of those clinics that have a nurse specialist, 
neurologists believe that because of the PD nurse specialist there are less Parkinson patients 
admitted to the neurology department and other departments in 40% and 17% of the 
hospitals respectively. 
DISCUSSION
PD patients are vulnerable especially during hospitalization and therefore might need extra 
care.4,5 There is some evidence that a PD patient can benefit from an early neurological 
consultation and overall a multidisciplinary approach seems desirable.4,5,9 However, data 
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presented in this chapter shows that in most hospitals admitted PD patients, whether or 
not having surgery, are just visited by the movement disorder team on special request of 
the treating specialist or PD patient. This might result in late consultation and these patients 
therefore may not have the advantage of multidisciplinary management. Although in most 
hospitals there is a PD nurse specialist, in the majority of the hospitals these were not 
involved in the care to the hospitalized PD patient. 
A problem seems to be that there is no warning system that alerts the movement disorder 
team of newly admitted PD patients. As such, a proactive approach from this team is difficult. 
Just 2 hospitals in the Netherlands reported of a protocol concerning the preoperative 
period. 
There are some limitations to the study. Unfortunately not all hospitals did reply the 
questionnaire, so we could have missed hospitals that have systems to trace new hospitalized 
PD patients and have written protocols. We were not able to analyze why the PD nurse 
specialist in many hospitals is not involved with the care for admitted PD patients. Maybe 
part-time jobs and busy schedules play a role.
However we believe that this study supports the need for a written protocol and extra 
attention to the specific problems Parkinson’s patients face when admitted to a hospital. 
CONCLUSIONS 
During hospitalization in many hospitals PD patients are not cared for with extra attention 
by a movement disorder team. There is still much room for improvement. To provide the 
necessary extra care for every hospitalized PD patients a written multidisciplinary protocol 
could be useful. 
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CHAPTER 7
General discussion
88 GENERAL DISCUSSION
INTRODUCTION
Parkinson’s disease (PD) is a common neurologic disorder mainly affecting the elderly.1,2 
PD is a progressive neurodegenerative disorder which has great influence on the patients’ 
quality of life.3,4 Next to this, PD has both major social and economic implications.5-8 The 
objective of the studies reported in the present thesis was to examine the problems 
hospitalized PD patients encounter in order to delineate ways and/or tools to improve the 
quality of care. Therefore, the first aim was to explore what is known about the extent of 
problems and related possible solutions (Chapter 2). To further investigate deterioration of 
Parkinson’s disease symptoms during hospitalization, we evaluated the prevalence and risk 
factors of deterioration including all wards. This was first done retrospectively, (Chapter 3) 
and secondly, prospectively, (Chapter 4) with the focus on motor symptoms. However, since 
non-motor symptoms contribute to disability and impaired quality of life with cognitive 
impairment as one of the most invalidating non-motor symptom,9-12 we also aimed to assess 
cognitive decline prospectively (Chapter 5). Next, we analyzed if PD patients are cared for 
with extra attention during hospitalization (Chapter 6).
In this general discussion I will focus on three main topics. I will discuss what the results of 
this thesis have added to the existing literature, and place these in a broader perspective.
These three topics are:
- Hospitalization and adverse events
- Medication errors
- Healthcare paradox 
Also, I will discuss general limitations of this thesis, its implications, and perspectives for 
further research.
HOSPITALIZATION AND ADVERSE EVENTS
Adverse events during the overall hospitalization of specific patient groups, as PD patients, 
have not been studied systematically. So the aim of this thesis was to analyze the problems 
PD patients are confronted with during hospitalization.
What we learned
In general, PD patients are hospitalized longer and have more complications than comparable 
control groups (Chapter 2). Infections and confusion are the most common complications, 
whether or not patients are having surgery (Chapter 2,3,4).  Both deterioration of motor 
and cognitive functions are more specific PD-related complications and have been 
reported during hospitalization in some retrospective studies (Chapter 2). We were 
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the first to systematically analyze proportions, reasons, and severity of deterioration, 
both retrospective and prospective, with the focus not only on Accident & Emergency 
departments and surgical wards, but also on other wards (Chapter 3,4,5). There is motor 
function deterioration in a substantial number of the admitted PD patients (Chapter 3,4). 
The most important hospitalization related risk factor for this deterioration was incorrect 
PD medication administration, followed by infections during hospitalization (Chapter 3,4). 
Both aspects have been attributed to motor exacerbations.13 In accordance with this, we 
found that many PD patients had a substantially worse cognitive function at discharge 
(Chapter 5). An episode of confusion (whether or not delirium) during hospitalization was 
the most important risk factor for cognitive deterioration at discharge (Chapter 5). Again, 
PD medication errors are an important factor for deterioration, as it is both a significant risk 
factor for deterioration as measured with the MMSE and for an episode of confusion during 
hospitalization (Chapter 5). Patients that had control of their own PD medication didn’t show 
motor function deterioration and had less cognitive function deterioration (Chapter 4,5).
Broader perspective
Some patients are more at risk for adverse events than others.14,15 In general, different 
specialties and departments show higher rates, especially specialties involving surgery.14,16 
Also, age seems important since the older the patient, the higher the rates of adverse 
events.14-18 For the elderly, most adverse events are more common, and the negative effects 
can be more severe.15,18 Drug and surgery related complications are the most common 
types.15,18 Important factors for this are the higher rate of complicated diseases and 
comorbidity for this older patient group, and the skills of caregivers to apply the existing 
knowledge to more complex situations.15,18 
An important associated factor for hospital encounters of PD patients is the number of 
comorbidities.19 These, in combination with the complexity of PD itself, with its vulnerable 
PD medication schedule and the average higher age, makes this patient group prone 
for adverse events. Since PD medication errors during hospitalization are not caused by 
the underlying disease but by the treatment team and result in patients with PD related 
disability, this can be seen as adverse events and should be classified as preventable. With 
the aging of the population and therefore the growing number of hospitalized PD patients, 
the awareness and prevention of adverse events for this specific population are becoming 
more important.18
MEDICATION ERRORS
As shown before, medication errors are frequent adverse events. In this thesis we aimed to 
analyze the extent this problem for hospitalized PD patients. 
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What we learned
We found that many PD patients are exposed to PD medication errors and administration 
of antidopaminergic drugs during admission (Chapter 2). PD patients did confirm this high 
rate of nonadherence to PD medication schedules as they reported this problem in 26% of 
the admissions (Chapter 3). Our observations in Chapter 4 showed even higher rates of PD 
medication problems, namely in 39% of the cases. Our results didn’t support the recently 
reported high rate of inappropriate antidopaminergic drugs prescription and administration, 
but did confirm existence of this problem (Chapter 4).20,21 These findings do agree with the 
high rates of adverse medication errors and support the necessary continuing awareness 
and attention for medication errors in general, and more specific, for medication related to 
PD during the hospitalization of this distinct, vulnerable patient group.
Broader perspective
Although the focus in this thesis is on PD patients, the problem of medication errors 
concerns all hospitalized patients in different departments.22-24 Especially older patients 
seem to have a high risk for errors because of comorbidities and polypharmacy.20,25,26 
Medication reconciliation, i.e. identifying of the most accurate medication list across the 
healthcare setting is important to prevent harm to the patient.25,27,28 Pinpointing the correct 
medication list however, can be a time consuming challenge because of poor self-reporting 
of prescribed medication and poor compliance.25,28,29 
Changes of environment or healthcare levels of a patient can result in unwanted changes 
or discontinuing of medication regimes, especially around hospitalization.27,29,30 Both 
admission to and discharge from the hospital are vulnerable moments for unintended 
changes in medication schedules and can harm the patient.27-30 Intervention studies have 
shown positive results in improving medication discrepancies for both moments, although 
the effects on patients’ disability are not clear.30 There seems to be an important role for the 
pharmacist in coordinating and controlling patients’ medication.27,30 Also, patient counseling 
and education before and after discharge can have positive results, and there might be a 
role for information technology.30 
To prevent PD medication errors during hospitalization an in-patient PD unit with a specially 
trained treatment team could be an option.31
HEALTHCARE PARADOX
Quality and safety of health care has received much more attention in recent years. 
Nevertheless, during hospitalization adverse events are common. At first glance, the aim of 
decreasing healthcare costs may contrast the possibility of offering better quality of care. 
Paradoxally, less money might result in better care. 
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What we learned
There are high complication rates and adverse events during the hospitalization of PD 
patients (Chapter 2,3,4,5). In most hospitals, PD patients are not treated with extra attention, 
despite the vulnerability of this specific patient group (Chapter 6). As a result, curing and 
harming the patient can coexist. Therefore, for the specific group of patients studied in 
this thesis, the hospitalized PD patient, there seems to be room for improvement which 
could result in better quality of care, a higher efficiency rate and lower costs. There are high 
rates of emergency visits and hospitalization rates per year (Chapter 2,3).19 The high number 
of admissions combined with average admission duration highlight that at any given time, 
in an average sized hospital, there is most likely a PD patient hospitalized (Chapter 3,4). 
Therefore, there should be a daily focus on this problem.
Broader perspective
Healthcare organizations have to meet increasing performance indicators. Total PD related 
direct and indirect costs are expected to increase as the size of the elderly population, and 
therefore the number of PD patients, grows.5-8 Financial resources are limited, however. 
Decision making is more and more based on cost-effectiveness studies, especially in chronic 
diseases such as PD.32 Limited available financial resources can result in a more critical 
look at conventional delivered care and might lead to novel ways to improve current 
care. This optimization of care might have a positive effect on relieving healthcare burden 
and quality of care and life. Prior studies have shown that changes in daily practice by 
healthcare providers can result in substantial cost reduction without negatively affecting 
patients’ satisfaction while improving the quality of delivered care.33,34 The paradoxal effect 
of decreasing healthcare costs might be better quality of care.
LIMITATIONS OF THE THESIS
There are limitations that could have influenced the outcomes. In both the retrospective 
and prospective study, there are relatively small numbers of hospitalized PD patients. The 
results presented in the retrospective study could have been influenced by recall bias, and 
there might have been observation bias in the prospective study since the observations 
were not blinded. We may have missed some admissions and not all patients gave informed 
consent. This could have caused selection bias. In the prospective study, not all patients were 
included immediately after admission, and therefore this vulnerary moment for medication 
errors35 was not analyzed properly. Next to this, the self-report of home PD medication 
schedules and preexistent motor and neuropsychological functions before admission was 
not objectified. During the admissions, the treating physicians did not analyze delirium 
structurally, and therefore there was no clear distinction between an episode of confusion 
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or delirium. However, since the problems PD patients encounter when admitted to the 
hospital, as presented in the systematic review (Chapter 2), do agree with results from 
the retrospective multicenter study (Chapter 3) and the single center prospective study, 
(Chapter 4,5) and data presented in Chapter 3 are confirmed by the results in Chapter 4, we 
believe the study results are generalizable and do not invalidate our conclusions.
IMPLICATIONS AND FUTURE PERSPECTIVES
Implications
First of all, if possible, hospitalization should be prevented. Close monitoring of the patient at 
the neurologist outpatient clinic and in its own environment, preferably in a multidisciplinary 
setting, could be helpful.19,36,37 When hospitalized, every PD patient should receive full 
attention (independent of admitted department or whether or not having surgery). Because 
of the vulnerability of PD patients and the unfamiliarity with PD of many treating physicians, 
the approach should be multidisciplinary from the moment of admission. Next to the treating 
team, neurology and/or geriatrics should be included in this multidisciplinary team. Since 
most hospitals have a PD nurse specialist (Chapter 6), they could have a coordinating and 
monitoring role. Special attention should be paid to personal PD medication regimes since 
this should be administrated as the home schedule. Self-administration of PD drugs could 
be considered when possible. There could be a role for a clinical pharmacist in controlling 
correct copying of home schedules and distribution of PD medication. Next to this, extra 
attention should be given to prevention and quick recognition of complications such as 
infections and episodes of confusion or delirium. Since every physician or nurse working in 
a hospital has to deal with PD patients, these suggestions should be included in a hospital-
wide protocol. The execution of the protocol could be supported additionally by education 
of hospital employees and PD patients and an (computerized) alert system to trace admitted 
PD patients. Another option could be the introduction of a specialist in-patient PD unit for 
every hospitalized PD patient, since a recent study showed positive effects on PD medication 
errors and length of stay.31
Future perspectives
Although there is increased attention for the problems the PD patient face when 
hospitalized, the positive effect of recommended interventions is not yet proven. Therefore, 
future studies should be taken to shed more light on these aspects. Preferably, this would 
be a multi-center prospective placebo-controlled randomized trial with sufficient number of 
patients, with the focus on both motor and non-symptoms. An in-patient PD unit could be 
the starting point.
GENERAL DISCUSSION 93
7
CONCLUSION
In conclusion, PD patients are hospitalized more frequently and generally longer than 
non-PD patients. During hospitalization, there is an increased complication rate of mainly 
infections and confusion. Many hospitalized PD patients have motor and cognitive function 
deterioration at discharge. The most important reasons for this are PD medication errors, 
confusion during hospitalization and infections. Measurements should be taken to prevent 
adverse events and improve care, preferably incorporated in a hospital-wide protocol, and 
future research should focus on analyzing the effects of these interventions. 
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98 SUMMARY
Parkinson’s disease (PD) is a progressive neurodegenerative disease that has major impact 
on the quality of life. The social and economic impacts are substantial. PD patients do 
have a high healthcare consumption rate, and the risk of hospitalization is high. During 
hospitalization, this vulnerable patient group is at risk for complications and other adverse 
events. In this thesis we studied the spectrum of problems patients with PD encounter 
during hospitalizations and explored those aspects that can be changed to improve quality 
of care.
Chapter 1 provides a general background of PD: Next to epidemiology, pathogenesis, the 
clinical diagnosis, the diverse symptoms, treatment options, and the different aspects that 
influence the quality of life are discussed. Subsequently, the high use of healthcare facilities 
by PD patients and related costs are described. More in detail, adverse events and the Dutch 
situation concerning the hospitalization of this vulnerable patient group are emphasized. 
Chapter 2 describes the results of a systematic review of the literature concerning 
hospitalization of PD patients. The main findings of this review are that PD patients have 
more emergency room encounters and are hospitalized more frequently than non-PD 
patients. They are hospitalized because of direct and indirect disease related morbidity and 
non-PD related causes. Also, the duration of hospitalization is generally longer and there are 
more complications during these admissions. There is a high risk for infections, confusion, 
decubitus, and falls, and there are indications that there is a high rate of PD medication 
errors. There are many unresearched recommendations concerning the improvement of 
care for inpatient PD patients. There are just a few studies on medication continuation 
during surgery and one study analyzing the effect of neurologic consultation. Overall, most 
studies were retrospective, had small patient numbers and were related to admissions of 
PD patients having surgery. 
In Chapter 3 we focused on the deterioration of motor function of PD patients during 
hospitalization. In this retrospective study, PD patients from three different hospitals 
were asked to answer a standardized questionnaire concerning a possible hospitalization 
in the last year. One third of the patients had one or more complications. One fifth of 
the cases reported deterioration of motor function during hospitalization. In the clinical 
files there was an underreporting of this PD deterioration. In a quarter of the admissions 
there were PD medication errors, and for this variable there was no significant difference 
between admission to a neurological or other ward or whether or not having surgery. The 
most important risk factor for motor function deterioration during hospitalization was PD 
medication errors followed by infections and a higher levodopa equivalent dose per day. 
In Chapter 4 we investigated the motor function outcomes during hospitalization 
prospectively. Different variables were analyzed to find possible factors that could cause 
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motor function deterioration. There was a clinically important worsening of motor 
function at discharge in more than one quarter of the admissions. During almost half of 
the admissions, there were complications, mainly confusion and infections. There were 
PD medication errors in almost four tenth of the admissions, resulting in longer (but not 
statistically significant) average admission duration. This last factor is the most important 
risk factor for motor function deterioration at discharge, followed by infections during 
hospitalization. None of the PD patients that had control of their own PD medication had 
motor function deterioration. 
Since cognitive impairment is one of the most invalidating non-motor symptoms, in Chapter 
5 we additionally prospectively analyzed cognitive functions during the hospitalization of 
PD patients using different cognitive function tests. There was cognitive deterioration at 
discharge in about a quarter of the admissions (a little less or more depending on the test 
that was used).  An episode of confusion or delirium, occurring in more than a quarter 
of the admissions is a significant risk factor for cognitive deterioration at discharge, and 
PD medication errors during hospitalization are related to an episode of confusion or 
delirium. Patients that deteriorated were admitted on average longer, however this was not 
statistically significant. 
In Chapter 6 we explored whether PD patients are cared for with extra attention by the 
treating team during hospitalization as per the higher complication risk. With the help 
of a questionnaire, we inventoried the care during hospitalization. In most hospitals in 
the Netherlands, there is no protocol available concerning the hospitalized PD patients. 
Neurological consultations are by specific request of the treating specialist. Although in 
most hospitals there is a PD nurse specialist available, in half of the hospitals they are not 
involved during the hospitalization of PD patients.
In Chapter 7, a general discussion of the main findings is given and placed in a broader 
perspective. This is followed by recommendations for improvement of care and for directions 
for future research. The chapter ends with concluding remarks. 
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De ziekte van Parkinson (ZvP) is een neurodegeneratieve aandoening met grote invloed op 
de kwaliteit van het leven. Daarnaast heeft deze ziekte een grote sociale en economische 
impact. Mensen met deze ziekte maken veel gebruik van gezondheidszorgvoorzieningen 
en hun kans op een ziekenhuisopname is groot. Tijdens een ziekenhuisopname loopt deze 
kwetsbare patiënten populatie een groot risico op complicaties en andere ongewenste 
gebeurtenissen. In dit proefschrift beschrijven we de verschillende problemen waar 
patiënten met de ZvP tijdens ziekenhuisopname mee geconfronteerd worden en maken we 
die aspecten inzichtelijk die tot een verbetering van de kwaliteit van zorg kunnen leiden. 
In Hoofdstuk 1 wordt een algemeen overzicht gegeven over de ZvP: Naast epidemiologie, 
pathogenese, de klinische diagnose, de verschillende klinische symptomen en behandelingen, 
worden de verschillende aspecten die van invloed zijn op de kwaliteit van leven vermeld. 
Vervolgens komen het grote gebruik van gezondheidszorgvoorzieningen door patiënten 
met de ZvP en gerelateerde kosten aan bod. Meer in detail worden problemen tijdens 
ziekenhuisopname en de Nederlandse situatie met betrekking tot deze kwetsbare patiënten 
groep belicht. 
In Hoofdstuk 2 worden de bevindingen van een systematisch overzicht van de bestaande 
literatuur over de hospitalisatie van Parkinsonpatiënten weergegeven. Patiënten met de 
ZvP bezoeken de spoedeisende hulp vaker en worden vaker opgenomen in het ziekenhuis 
dan patiënten die deze aandoening niet hebben. Oorzaken voor ziekenhuisopnames zijn 
zowel direct als indirect met de ziekte gerelateerde comorbiditeit als oorzaken die los staan 
van deze aandoening. De ziekenhuisopnames zijn over het algemeen langer en er zijn meer 
complicaties. Er is een hoog risico op infecties, verwardheid, decubitus en valpartijen en er 
zijn aanwijzingen dat er veel met de ZvP gerelateerde medicatie fouten worden gemaakt. Er 
zijn veel niet wetenschappelijk onderzochte adviezen met betrekking tot het verbeteren van 
de zorg beschreven. Er zijn slechts enkele studies die het continueren van ZvP gerelateerde 
medicatie beschrijven tijdens een operatie en er is één studie die kijkt naar het effect van een 
neurologische consultatie. Over het algemeen waren de meeste studies retrospectief, was 
er slecht kleine aantal patiënten geïncludeerd en hadden de meeste artikelen betrekking op 
ziekenhuisopnames van patiënten die een operatie ondergingen.  
In Hoofdstuk 3 onderzochten we het beloop van  de motorische symptomen van patiënten 
met de ZvP tijdens een ziekenhuisopname. In deze retrospectieve studie is aan patiënten 
met de ZvP van drie verschillende ziekenhuizen gevraagd een gestandaardiseerde vragenlijst 
in te vullen die betrekking had op een mogelijk ziekenhuisopname in het voorafgaande 
jaar.  Eén derde van de patiënten gaf aan één of meer complicaties gehad te hebben. Eén 
vijfde melde motorische verslechtering tijdens ziekenhuisopname. In de klinische dossiers 
was er een onderrapportage van deze verslechtering. Tijdens een kwart van de opnames 
waren er met de ZvP gerelateerde medicatie fouten. Er was voor deze variabele geen 
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significant verschil was tussen neurologische en niet neurologische afdelingen en ook 
niet voor patiënten die wel of geen operatie hebben gehad. De belangrijkste risicofactor 
voor motorische verslechtering tijdens ziekenhuisopname was ZvP gerelateerde medicatie 
fouten, gevolgd door infecties en een hogere levodopa equivalente dosis per dag. 
In Hoofdstuk 4 werd het beloop van de motorische functie van patiënten met de ZvP gedurende 
een ziekenhuisopname prospectief geanalyseerd. Verschillende variabelen zijn bekeken om 
er achter te komen welke de oorzaak zouden kunnen zijn voor motorische verslechtering. 
In meer dan een kwart van de ziekenhuisopnames was er een klinisch relevante motorische 
verslechtering bij ontslag. Gedurende bijna de helft van de opnames waren er complicaties, 
vooral verwardheid en infecties. In viertiende deel van de ziekenhuisopnames waren er 
ZvP gerelateerde medicatie fouten. Dit resulteerde in langere ziekenhuisopnames alhoewel 
het verschil niet significant was. ZvP gerelateerde medicatie fouten was de belangrijkste 
risicofactor voor een slechtere motorische functie bij ontslag, gevolgd door infecties tijdens 
opname. Van alle patiënten die ZvP gerelateerde medicatie in eigen beheer hadden, had er 
geen een motorische verslechtering.
In Hoofdstuk 5 werd vervolgens prospectief gekeken naar de cognitieve functies van 
Parkinsonpatiënten tijdens de ziekenhuisopnames. Hierbij is gebruik gemaakt van 
verschillende cognitieve testen. In ongeveer een kwart (afhankelijk van de gebruikte test 
wat meer of minder) van de opnames was er een cognitieve verslechtering bij ontslag. Een 
periode van verwardheid of delirium tijdens opname kwam voor in meer dan een kwart van 
de opnames. Dit is een significante risicofactor voor cognitieve verslechtering bij ontslag. 
ZvP gerelateerde medicatie fouten is gerelateerd aan een periode van verwardheid of 
delirium. De patiënten die verslechterde hadden gemiddeld langere ziekenhuisopnames 
(niet significant). 
In Hoofdstuk 6 hebben we gekeken of patiënten met de ZvP van het behandelteam extra 
aandacht krijgen tijdens een ziekenhuisopname gezien het hogere complicatierisico. Met 
een vragenlijst inventariseerden we de zorg voor deze patiënten tijdens een ziekenhuis 
opname. Het bleek dat in de meeste Nederlandse ziekenhuizen geen protocol beschikbaar 
was waarin de zorg beschreven werd die betrekking heeft op de in een ziekenhuis 
opgenomen Parkinsonpatiënt. Ook bleek de neuroloog in de meeste ziekenhuizen niet 
standaard bij iedere patiënt met de ZvP in medebehandeling was. Dit gebeurde meestal pas 
na specifiek verzoek van de hoofdbehandelaar. Alhoewel er in de meeste ziekenhuizen een 
Parkinsonverpleegkundige werkzaam is, zijn deze in de helft van de gevallen niet betrokken 
bij zorg gedurende de opname. 
In hoofdstuk 7 wordt een algemene discussie gevoerd en worden de bevindingen in een 
breder perspectief geplaatst. We geven aanbevelingen voor het verbeteren van de zorg en 
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voor het verrichten van toekomstig wetenschappelijk onderzoek. Het hoofdstuk eindigt met 
enkele conclusies.
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INTRODUCTION
Society increasingly demands accountability for work performed, especially when public 
money is spent. This applies not only to business and government agencies, but also to 
scientific research. 
Valorisation is ‘the process of creating value from knowledge, by making this knowledge 
available and suitable for economic and social exploitation and to translate this knowledge 
into products, services, processes and new business’. Therefore research results should be 
brought to attention of potential users and must be translated into social, economic and/or 
financial value.1,2 
ECONOMIC AND SOCIAL RELEVANCE OF RESULTS OF THIS THESIS
In this thesis we gave some suggestions for improvement of care during the hospitalization 
of Parkinson’s disease (PD) patients, e.g. self-administration of PD medication, proactive 
multidisciplinary approach, education of health care professionals, and prevention of 
infections and delirium (Chapter 3,4,5,6,7). These recommendations might eventually result 
in both economic and social valorisation. 
Economic	valorisation
In the Netherlands in 2011 the total number of patients with Parkinsonism was estimated 
29,000. In the next decades the median age of the population will rise and as a result the 
number of PD patients will probably increase.3,4 
Patients with PD use a lot of healthcare facilities and as such related costs for PD and other 
forms of Parkinsonism are high. In the Netherlands in 2011 this was estimated at 267 million 
Euro per year.5-7 Hospital admissions account for 8.5% of these costs.7 We showed in this thesis 
that hospital stay is longer due to iatrogenic deterioration of PD symptoms. Strict adherence 
to our recommendations will most likely result in a decrease of length of hospital stay with 
concomitant decrease of costs. Although we didn’t do a proper cost-effectiveness study, 
which would be preferred, we can roughly estimate the unnecessary direct hospitalization 
costs concerning admissions with PD medication errors. Chapter 4 shows that medication 
errors occurred in 39% of admissions, which resulted, on average, in a longer hospitalization 
of 1.7 days compared to admissions without PD medication errors. PD hospitalization costs 
are estimated at 23 million Euro per year, spread over 1492 hospitalizations with an average 
duration of 12.6 days.7 If we extrapolate our findings to the Dutch situation it means that 
in 576 hospitalizations (i.e. 39% of total admission number) per year PD medication errors 
occur resulting in 979 extra hospitalization days (i.e. 576 x 1.7 days) per year. On average 
the cost of an admitted PD patient in The Netherlands health care system is 1,207 Euro 
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per day. This results, for the Netherlands only, in 1.18 million Euro per year of extra direct 
hospitalization costs because of PD medication errors, which is preventable and therefore 
unnecessary spent public money. 
Improvement of care during hospitalization by implementing the recommendations of this 
thesis will result in reducing needless spending of both private and public money, which 
therefore becomes available for other (community related) purposes. 
Social	valorisation
PD has a high impact on quality of life of PD patients.8-10 Moreover, the patient is not the 
only one affected by the disease. Because of the disease, with both motor and non-motor 
symptoms, the patient needs a lot of attention by partner, children, and/or other caregivers, 
certainly in the more advanced stages of the disease. Now that the government has come 
up with the ‘participation society’ the pressure on the caregivers will only increase. A lot of 
these ‘voluntary’ caregivers have busy lifes (own household, jobs), even without this extra 
care they (have to) provide. Although hospitalization of PD patients for some caregives 
might be a temporarily releaf, deterioration of PD symptoms will result in additional work 
after discharge from hospital. 
This thesis shows that improvement of care during the hospitalization of PD patients will not 
only result in better health conditions of the PD patient but will also cause less distress and 
higher satisfaction for the caregiver.
PRODUCTS AND PROCESSES
To accomplish the recommendations, new developments will be valuable to implement. 
This could include an electronic notification that warns the hospital’s Parkinson’s team when 
a vulnerable PD patient is admitted. Another point of focus could be PD medication errors, 
for example by introducing a warning system that informs a nurse that the patient needs his 
or her medication. One option is a nurse’s mobile phone notification on specific moments 
linked to the electronic medication systems (which may be coupled to the home pharmacy 
to provide an accurate home medication schedule). Another option, although maybe less 
effective but easier to introduce, could be the distribution of cards with (warning) instructions 
that the patient or caregiver can leave in the patient’s room in case of hospitalization. 
Our data support the introduction of new (technological) products to improve hospital care 
to lead to both social and economic benefit.
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TARGET GROUPS THAT CAN BENEFIT
PD patients are a vulnerable patient group for adverse events during hospitalization. One 
of the causes of these adverse events is due to difficult medication schemes. There are 
however more older patient groups with complex medication regimes that are at increased 
risk for complications during hospitalization. Examples are patients with dementia, cancer, 
and multimorbidity in general.11 
Other specialties and its patient population could benefit from the recommendations in 
this thesis to improve care, since most of these are generalizable. Next to this, the methods 
we used in this thesis to analyze a specific vulnerable patient group could be interesting for 
other patient groups as well. This could result in other specific recommendations to improve 
care for these patients. 
CONCLUSION
Valorisation of our study results are related to reduction of direct health care costs by strict 
adherence to our recommendations, which are easy to implement and to the development 
of new IT products based on our findings and recommendations that might be offered to the 
clinician to further improve care for PD patients. As such, our study and recommendations 
could lead to both economic and social valorisation.
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ADDITIONAL FILE 1- INTRODUCTION LETTER QUESTIONNAIRE 
RETROSPECTIVE STUDY
Dear Sir/Madam,
You are being treated for Parkinson’s disease in our hospital and/or you use drugs that are 
prescribed for this disease. 
Many patients with Parkinson’s disease have told us that they have deteriorated after a 
hospital stay. With this survey we would like to know your experience in this. With this 
information we strive to improve the quality of our patient care. 
Therefore we would very much appreciate your cooperation to complete the attached 
questionnaire. 
Confidential	data	processing
Personal information is strictly confidential and processed completely anonymously. Nobody 
will be able to determine on the basis of your answers who gave these answers.  
Voluntary	participation
Participation to this research is completely voluntary. You may refuse to participate without 
given a reason. Of course this will not influence your further treatment. 
Questionnaire
You will notice that the questions resemble the questions normally asked by your treating 
doctor. We would prefer that you answer the questionnaire yourself (the patient), together 
with, if applicable, your partner or caregiver.
When answering the questions in case you are not the patient, all questions do relate to the 
patient. 
Could you please return the questionnaire within two weeks. There is an envelope attached, 
there is no stamp required. You can also hand it over at the outpatient clinic.  
If you have any questions or remarks concerning this survey please contact us: telephone 
number.
We try to maintain our address file as accurately as possible. Obviously, this questionnaire 
might have been delivered to you by mistake. It is also possible that this survey is sent to you 
on a very inappropriate moment for you or your family. If so, we apologize. 
Thank you for your cooperation.
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ADDITIONAL FILE 2 - QUESTIONNAIRE RETROSPECTIVE STUDY
A. General information
1. Who answers this questionnaire?
 Patient 
 Patient with the help of partner or caregiver 
 Partner and/or caregiver
 Other, namely ………………….(please mention the relationship with the patient)
2. What is your date of birth? (of the patient):   
……...-……….-……… (day-month-year)
3. What is your gender? 
 Male
 Female
4. What is your civil status? 
 Living on your own
 Living together with partner, not married
 Living together with somebody else than partner, namely …………………..
 Married
 Widower/Widow
 Divorced 
 Other, namely ………………………….................
5. What is your nationality?
 Dutch
 Belgium
 German
 Turkish
 Moroccan
 Other, namely ………………………….............
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B. Care related questions
6. Have you been admitted to a hospital in the previous year?
 No (go to question 18)
 Yes, namely: 
- Please mention all admissions both for neurology and other specialties, also if there were 
multiple admissions per specialty. 
- Please mention for every admission if you did have surgery or not (cross out what is not 
applicable at ‘Yes / No’)
- Please mention all complications, if any, even if there were more than one per admission. 
Please mention if this complication was before and/or after a possible surgery (cross out 
what is not applicable at ‘Before / after/ before and after’).
(Examples	of	complications: Confusion, hallucinations, pneumonia, urinary tract infection, 
wound infections, thrombosis, falls, worsening of motor function, mood disorders, 
pulmonary embolism, memory impairment etc.) 
Example 1  ..Internal medicine …pneumonia… Yes/No  no complication Before/after/before 
and after 
  2  ..Surgery…          …hipfracture…  Yes / No …thrombosis…   Before/after/before 
and after
                                                                       ....confusion…     Before/after/before and 
after
 
Admission  Specialty         illness/complaint   Surgery  Complication(s)  Before and/or after a 
number                                                                                                                    possible surgery  
1         ……………..            ..…………………   Yes / No …………………   Before/after/before and after  
   
  …………………   Before/after/before and after 
   
  …………………   Before/after/before and after
2         ……………..            ..…………………   Yes / No …………………   Before/after/before and after  
  …………………   Before/after/before and after 
   
  …………………   Before/after/before and after
3         ……………..            ..…………………   Yes / No …………………   Before/after/before and after  
  …………………   Before/after/before and after 
  …………………   Before/after/before and after
4         ……………..            ..…………………   Yes / No …………………   Before/after/before and after  
  …………………   Before/after/before and after 
  …………………   Before/after/before and after
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5         ……………..            ..…………………   Yes / No …………………   Before/after/before and after  
  …………………   Before/after/before and after 
  …………………   Before/after/before and after
The following questions can refer to an ‘admission number’, you can find it at question 6. 
7. Was Parkinson’s disease medication distributed according to the same schedule as you 
take your medication at home? (more than one answer possible) 
 Not applicable, no admission
 Yes
 No, the time of medication distribution was not the same at admission number(s) 
…………... (see question 6)
 No, the kind of Parkinson’s disease medication did not match at admission 
number(s)………….(see question 6)
 Don’t know
 Other answer, namely ………………………….................
8. Was there during one of the admissions an interruption of Parkinson’s disease 
medication? (more than one answer possible)  
 Not applicable, no admission
 No
 Yes, during a surgery, namely at admission number(s) ……….....(see question 6)
 Yes, this was on purpose namely because of …………………………………at admission 
number(s)……..(see question 6)
 Yes, this was not on purpose, namely at admission number(s) …………….(see question 6)
 Don’t know
 Other answer, namely ………………………….................
9. Did you have to point out to the personnel that there was a problem with the 
distribution of Parkinson’s disease medication? (more than one answer possible)  
 Not applicable, no admission
 No
 Yes, point out incorrect distribution time, namely at admission number(s)……………(see 
question 6)
 Yes, point out incorrect Parkinson’s disease medication, namely at admission number(s) 
……...(see question 6)
 Yes, point out that Parkinson’s disease medication was forgotten, namely at admission 
number(s) ……...(see question 6)
 Don’t know
 Other answer, namely ………………………….................
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10. Did you have to point out to the personnel that there was a problem with the 
distribution of Parkinson’s disease medication after a possible surgery?   (more than one 
answer possible)  
 Not applicable, no surgery
 No, I did have surgery but there was no problem with the medication distribution after 
the surgery at admission number(s) ……...(see question 6)
 Yes, point out incorrect Parkinson’s disease medication, namely at admission number(s) 
……...(see question 6)
 Yes, point out that Parkinson’s disease medication was forgotten, namely at admission 
number(s) ……...(see question 6)
 Yes, point out that there was incorrect Parkinson’s disease medication, namely at 
admission number(s) ……...(see question 6)
 Don’t know
 Other answer, namely ………………………….................
11. Was there a deterioration of Parkinson’s disease (i.e. decline in motor function) 
during the admission? (more than one answer possible)  
 Not applicable, no admission
 No, no deterioration (go to question 14)
 Yes, namely ……………………………………………(please point out what aspect deteriorated) at 
admission number(s) ……...(see question 6)
 Don’t know
 Other answer, namely ………………………….................
12. Did this deterioration start after a possible surgery? (more than one answer possible) 
 Not applicable, no surgery
 Not applicable, no deterioration
 No, deterioration started already before surgery, namely at admission number(s) ……...
(see question 6)
 Yes, deterioration started after surgery, namely at admission number(s) ……...(see 
question 6)
 Don’t know
 Other answer, namely ………………………….................
13. Did this deterioration start after interruption of Parkinson’s disease medication?
 Not applicable, no admission
 Not applicable, no deterioration
 No
 Yes, namely at admission number(s) ……...(see question 6)
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 Don’t know
 Other answer, namely ………………………….................
14. Was there a deterioration of Parkinson’s disease after the admission?
 Not applicable, no admission
 No, no deterioration
 Yes, namely ……………………………………………(please point out what aspect deteriorated) at 
admission number(s) ……...(see question 6)
 Don’t know
 Other answer, namely ………………………….................
15. How long did the deterioration of Parkinson’s disease last? (more than one answer 
possible)  
 Not applicable, no admission
 No deterioration during or after the admission at admission number(s) ……...(see question 
6)
 Deterioration lasted for: (if deterioration during or after more than one admission please 
mention the duration of all of them)  
     …….days, namely at admission number(s) ……...(see question 6)
     …….weeks
     …….months
     …….days, namely at admission number(s) ……...(see question 6)
     …….weeks
     …….months
     …….days, namely at admission number(s) ……...(see question 6)
     …….weeks
     …….months
 No full recovery from deterioration, namely at admission number(s) ……...(see question 
6)
 Don’t know
16. Was there contact with a Parkinson’s disease nurse specialist or another allied 
healthcare facility during the admission?  (for example occupational therapist, speech 
therapist, etc.) 
 Not applicable, no admission
 No
 Don’t know
 Yes, namely :  
      Parkinson’s disease nurse specialist at admission number(s) ……... (see question 6)
      Physical therapy at admission number(s) ……...(see question 6)
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      Occupational therapy at admission number(s) ……...(see question 6)
      Speech therapy at admission number(s) ……...(see question 6)
      Psychology at admission number(s) ……...(see question 6)
      Social worker at admission number(s) ……...(see question 6)
      Another allied healthcare facility, namely:
           Allied healthcare facility              admission number(s): see question 6
           ………………….                        ………
           ………………….                        ………
17. Do you use more frequently allied healthcare facilities after the admission compared 
to before? 
 Not applicable, no admission
 Don’t know
 No
 Yes, namely :  
      Parkinson’s disease nurse specialist at admission number(s) ……...
   (see question 6)
      Physical therapy at admission number(s) ……...(see question 6)
      Occupational therapy at admission number(s) ……...(see question 6)
      Speech therapy at admission number(s) ……...(see question 6)
      Psychology at admission number(s) ……...(see question 6)
      Social worker at admission number(s) ……...(see question 6)
      Another allied healthcare facility, namely:
           Allied healthcare facility              admission number(s): see question 6
           ………………….                        ………
           ………………….                       ………
18. Where do you live now?:
 Independent house
 Assisted living
 Elderly home
 Nursing home
 Other answer, namely ………………………….................
19. If you use medication, do you take the medication as prescribed by the doctor? 
(more than one answer possible)  
 Yes, the correct medication at the correct times
 No, I don’t take the medication at all
 No, I sometimes forget medication
 No, I often forget medication
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 No, I don’t take the medication at the prescribed times because 
    ……………………….
 No, I often take extra medication because of
 …………………………………………..
 No, I often don’t take medication because of side effects 
 No, I often don’t take medication because of the costs
 No, I often don’t take medication because I have to many tablets
 Other answer, namely ………………………….................
C. Disease relates questions
20. Do you have (had) tremors? (more than one answer possible)  
 No
 Yes, the head
 Yes, the arms/hands
 Yes, the legs/feet
 Other answer, namely ………………………….................
21. Do you have (had) stiffness/rigidity? (more than one answer possible)  
 No
 Yes, the arms
 Yes, the legs 
 Other answer, namely ………………………….................
22. Do you have (had) bradykinesia or did you become slower because of Parkinson’s 
disease?
 No
 Yes 
23. Do you have (had) postural instability?
 No
 Yes, but I never fall
 Yes, I fall sometimes
 Yes, I fall often
 Yes, I can not walk anymore 
 Other answer, namely ………………………….................
24. If you fall, how often do you fall on average per month?
…….. times on average per month
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25. In what year did the symptoms (as described in question 2 to 24) of Parkinson’s 
disease begin?
 In the year :  …………….. 
 Not applicable
 Don’t know
26. Do you currently have one or more of the following symptoms? (more than one 
answer possible)  
 Problems with turning over in bed
 Reduced smell
 Problems with writing
 Problems with using cutlery
 Joint pain
 Back pain
 Cramps
 Pain, namely  …………………
 Changed sexual behaviour, namely …………..
 Psychosis/hallucinations
 Dyskinesia
 On-off moments
 Depressed mood
 Anxiety and/or panic attacks
 Light-headedness when standing quickly
 Swallow problems
 Choking
 Problems with urination
 Problems with defecation
 Memory problems
 Behaviour problems
 Sensation of tingling (paresthesia)
 Sleep disorders
 Problems with breathing, namely …………..
 Other answer, namely ………………………….................
27. Which of the following answers fits you the most? (just one answer possible)
 No signs of the disease
 Unilateral symptoms only, no impairment of balance
 Bilateral symptoms, no impairment of balance 
 Mild to moderate disease symptoms, balance impairment, physically independent
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 Severe disability, but still able to walk or stand unassisted
 Needing a wheelchair or bedridden unless assisted
28. Do you currently take medication?
 Yes
 No (go to question 3)
29. What medication do you currently take? (all drugs for all diseases)   
Please also mention any side effects.
Optionally, a copy of your medication prescriptions can be added.
(Example:	sinemet			125mg						3	times	per	day	2	tablets									Drowsiness)
Name of drugs:         Dose        How many times a day         Side effect
                                                     how many tablets         
1 …………………  ………       …………………………        …………………….
2 …………………  ………       …………………………        …………………….
3 …………………  ………       …………………………        …………………….
4 …………………  ………       …………………………        …………………….
5 …………………  ………       …………………………        …………………….
6 …………………  ………       …………………………        …………………….
7 …………………  ………       …………………………        …………………….
8 …………………  ………       …………………………        …………………….
9 …………………  ………       …………………………        …………………….
10 .………………   ………       …………………………       …………………….
11 .………………   ………       …………………………       …………………….
30. Do you have any questions or remarks concerning this survey? 
……………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………
END OF QUESTIONNAIRE
Could you please verify that you have answered all the questions completely?
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ADDITIONAL FILE 3 - QUESTIONNAIRE PROSPECTIVE STUDY 
Timepoint 1    
A. General information
1. Patient identification number: …..
2. Investigator: …..
3. Date of measurement …-…-… (day-month-year)
4. Day of inclusion:
 Day 1
 Day …
 Because of:
  Patient related issues, namely …
  Logistic reasons, namely …
  Other reasons, namely ….
5. What is your age?
….. years
6. What is your gender? 
 Male
 Female
7. What is your civil status? 
 Living on your own
 Living together with partner, not married
 Living together with somebody else than partner, namely …………………..
 Married
 Widower/Widow
 Divorced 
 Other, namely ………………………….................
8. Where do you live?
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 In a house, independent
 Assisted living
 Home for the elderly
 Nursing home
 Other, namely ………
B. Disease related questions
9. How many years ago did the Parkinson disease related symptoms start? 
 …. years
 Unknown
10. Do you often fall at home? 
 No, never.
 Yes, approximately …. times a month
11. Do you currently have one or more of the following symptoms? (more than one 
answer possible)  
 Problems with turning in bed
 Reduced smell
 Problems with writing
 Problems with using cutlery
 Joint pain
 Back pain
 Cramps
 Pain, namely  …………………
 Changed sexual behaviour, namely …………..
 Psychosis/hallucinations
 Dyskinesia
 On-off moments
 Depressed mood
 Anxiety and/or panic attacks
 Light-headedness when standing quickly
 Swallow problems
 Choking
 Problems with urination
 Problems with defecation
 Memory problems
 Behavior problems
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 Sensation of tingling (paresthesia)
 Sleep disorders
 Problems with breathing, namely …………..
 Other answer, namely ………………………….................
12. Do you have, besides Parkinson’s disease, other medical conditions? (more than one 
answer possible).
 No
 Yes, hypertension
 Yes,  diabetes
 Yes, heart problems namely ……..
 Yes, persistent neurologic deficit after a stroke, namely …..
 Yes, epilepsy
 Yes, kidney disease, namely …..
 Yes, liver disease, namely ……
 Yes, artrosis of the joints
 Yes, rheumatoid arthritis
 Yes, osteoporosis
 Yes, cataract
 Yes, enlarged prostate
 Yes, skin disease namely ……
 Yes, cancer, namely …..
 Yes, other, namely ……
13. Are you currently using any medication?
 Yes
 No
14. If you are using medication, which one?  (every medication for all medical 
conditions). 
Medication name:  Dose  Times a day
1.
2.
3.
4.
5.
6.
7.
8.
9,
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10.
11.
12.
13.
14.
15.
15. At home, do you use your Parkinson medication accordingly to the schedule as 
prescribed by your doctor?
 Not applicable, not using Parkinson medication
 No, different timing because ……..
 No, not taking some pills because ……
 Yes
 Other, namely ……
C. Care related questions
16. What is the admission reason (diagnose and complaints)?
17. For what specialty are you currently admitted? 
18. Is it a planned/elective admission? 
 No
 Yes
 Other, namely ……
19. Is it an emergency admission?
 No
 Yes
 Other, namely …..
20. Are you admitted through the emergency department? 
 No
 Yes
 Other, namely ……
21. Did you have surgery? 
 No
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 Yes, namely
 1. ………………. Urgency/planned
 2. ………………. Urgency/planned
 3. ……………….. Urgency/planned
 4. ……………….. Urgency/planned
(please mention all surgeries, and what sort of surgery you had)
 Other, namely …………..
22. Were there any complications during your stay in the hospital?
Please note all complications, and point out if they happened before or after surgery (if 
applicable). Examples of complications (walkthrough with patient):
Confusion, delirium, hallucinations, decubitus ulcer, wound infections, pneumonia, upper 
airway infection, cystitis, other infections, bladder problems, constipation, cardiovascular 
events, TIA, stroke, deep venous thrombosis, fall, fractures, gastrointestinal problems, pain, 
deterioration of motor function, increased rigidity, mood problems, pulmonary embolism, 
memory problems, etc. 
 No
 Yes
Complication(s):            Before and/or after surgery
a. ……………………. Before/ After/ Before and after/During/ Not applicable
b. ……………………. Before/ After/ Before and after/During/ Not applicable
c. ……………………. Before/ After/ Before and after/During/ Not applicable
d. ……………………. Before/ After/ Before and after/During/ Not applicable
e. ……………………. Before/ After/ Before and after/During/ Not applicable
23. Was there during this admission an episode of confusion / delirium? 
 No
 Yes. 
If answered yes, please point out the confusion / delirium was yet present before 
hospitalization:
 No, not present before hospitalization
 Yes, present before hospitalization
 Don’t know
24. Are there any other specialists consulted during the admission? 
 No
 Yes, namely
 1. Specialty:……………….. Reason: ……………………
2. Specialty:……………….. Reason: ……………………
3. Specialty:……………….. Reason: ……………………
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4. Specialty:……………….. Reason: ……………………
5. Specialty:……………….. Reason: ……………………
6. Specialty:……………….. Reason: ……………………
 Other, namely…….
25. Is the patient currently admitted to the intensive care unit (ICU)? 
 No
 Yes,   Specialty: …………………………………..
 Reason: ……………………………………..
 Length (days):  …………………………..
 Course: ……………………………………..
Consulted specialists:
1. Specialty:……………….. Reason: ……………………
2. Specialty:……………….. Reason: ……………………
3. Specialty:……………….. Reason: ……………………
4. Specialty:……………….. Reason: ……………………
5. Specialty:……………….. Reason: ……………………
6. Specialty:……………….. Reason: ……………………
Complication(s):
a. ……………………. Before/ After/ Before and after/During/ Not applicable
b. ……………………. Before/ After/ Before and after/During/ Not applicable
c. ……………………. Before/ After/ Before and after/During/ Not applicable
d. ……………………. Before/ After/ Before and after/During/ Not applicable
26. Is the patient currently admitted to the medium care unit (MCU)?
 No
 Yes, Specialty: …………………………………..
 Reason: ……………………………………..
 Length (days):  …………………………..
 Course: ……………………………………..
Consulted specialists:
1. Specialty:……………….. Reason: ……………………
2. Specialty:……………….. Reason: ……………………
3. Specialty:……………….. Reason: ……………………
4. Specialty:……………….. Reason: ……………………
5. Specialty:……………….. Reason: ……………………
6. Specialty:……………….. Reason: ……………………
Complication(s):
a. ……………………. Before/ After/ Before and after/During/ Not applicable
b. ……………………. Before/ After/ Before and after/During/ Not applicable
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c. ……………………. Before/ After/ Before and after/During/ Not applicable
d. ……………………. Before/ After/ Before and after/During/ Not applicable
27. Did you fall during the hospital stay? 
 No
 Yes, …… times
If you did, please point out if this was before of after surgery (if applicable):
1. ……………………. Before/ After/ Before and after/During/ Not applicable
2. ……………………. Before/ After/ Before and after/During/ Not applicable
3 ……………………. Before/ After/ Before and after/During/ Not applicable
4. ……………………. Before/ After/ Before and after/During/ Not applicable
 Don’t know
 Other, namely ………
28. Was Parkinson’s disease medication distributed according to the same schedule as 
you take your medication at home? (more than one answer possible) 
 Not applicable, no Parkinson’s disease medication
 Yes
 No, the time of medication distribution was not the same 
 No, the kind of Parkinson’s disease medication did not match 
 Don’t know
 Other answer, namely ………………………….................
29. Was there during one of the admissions an interruption of Parkinson’s disease 
medication? (more than one answer possible)  
 Not applicable, no Parkinson’s disease medication
 No
 Yes, during surgery
 Length of interruption: …… hours/ days
 If more than one surgery, please write down all interruptions.
 Yes, this was on purpose because of ……………………
 Yes, this was not on purpose
 Don’t know
 Other answer, namely ………………………….................
30. Did you have to point out to the personnel that there was a problem with the 
distribution of Parkinson’s disease medication? (more than one answer possible)  
 Not applicable, no Parkinson’s disease medication
 No
 Yes, point out incorrect distribution time
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 Yes, point out incorrect Parkinson’s disease medication
 Yes, point out that Parkinson’s disease medication was forgotten
 Don’t know
 Other answer, namely ………………………….................
31. Did you have to point out to the personnel that there was a problem with the 
distribution of Parkinson’s disease medication after a possible surgery?   (more than one 
answer possible)  
 Not applicable, no Parkinson’s disease medication
 Not applicable, no surgery
 No, I did have surgery but there was no problem with the medication distribution after 
the surgery.
 Yes, point out incorrect Parkinson’s disease medication
 Yes, point out that Parkinson’s disease medication was forgotten
 Yes, point out that there was incorrect Parkinson’s disease medication 
 Don’t know
 Other answer, namely ………………………….................
32. Was there deterioration of Parkinson’s disease (i.e. decline in motor function) during 
the admission? (more than one answer possible)  
 No, no deterioration 
 Yes, namely …………………(please point out what aspect deteriorated) 
 Don’t know
 Other answer, namely ……………
33. Did this deterioration start after a possible surgery? (more than one answer possible) 
 Not applicable, no surgery
 Not applicable, no deterioration
 No, deterioration started already before surgery
 Yes, deterioration started after surgery
 Don’t know
 Other answer, namely ………………………….................
34. Did this deterioration start after interruption of Parkinson’s disease medication?
 Not applicable, no Parkinson’s disease medication
 Not applicable, no deterioration
 Not applicable, no surgery
 No
 Yes
 Don’t know
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 Other answer, namely …………………
35. Was there contact with a Parkinson’s disease nurse specialist or another allied 
healthcare facility during the admission? (for example occupational therapist, speech 
therapist, etc.) 
 No
 Don’t know
 Yes, namely :  
 Parkinson’s disease nurse specialist
   Physical therapy 
   Occupational therapy 
   Speech therapy 
                          Psychology 
    Social worker 
 Another allied healthcare facility, namely:
                 Allied healthcare facility 
                                        ………………….                      
            ………………….                       
36. Did the investigator contact the nurses or/and doctors about any health related 
problems concerning the patient? 
 No
 Yes,  contact with: nurse / doctor / consultant/ other ……
 concern and advise:  …………………………………………….
 therapeutic consequence:  …………………………………..
37. Comments
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................  
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Timepoint 2
A. General information
1. Patient identification number: …..
2. Investigator:
3. Day of examination:
4. If it’s not the last or next-to-last day of the admission please point out the reason: 
 Patient related issues, namely……………….
 Logistic reasons, namely…………….
 Other, namely……………………………………..
B. Disease related questions
5. If you are using medication, which one? (every medication for all medical conditions)
Medication name:  Dose  Times a day
1.
2.
3.
4.
5.
6.
7.
8.
C. Care related questions
6. Is the diagnosis at admission identical to the diagnosis at discharge? 
 Yes, the diagnosis didn’t change and there were no additional diagnoses. 
 Yes, the diagnosis didn’t change but there were additional diagnoses.
 No
 Other, namely ………
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7. What is the definitive diagnosis at discharge?  (please note all diagnoses)
1. ………………..
2. ………………..
3. ………………..
4. ………………..
 Other, namely …………………….
8. For what specialty are you admitted? (if there are more than one please note all 
specialties). 
1. ………………..
2. ………………..
3. ………………..
4. ………………..
9. Are there any other specialists consulted during the admission? 
 No
 Yes, namely
 1. Specialty:……………….. Reason: ……………………
2. Specialty:……………….. Reason: ……………………
3. Specialty:……………….. Reason: ……………………
4. Specialty:……………….. Reason: ……………………
5. Specialty:……………….. Reason: ……………………
6. Specialty:……………….. Reason: ……………………
 Other, namely…….
10. Did you had surgery? 
 No
 Yes, namely (please mention if the surgery was planned/elective or urgency)
 1. ………………. Urgency/planned
 2. ………………. Urgency/planned
 3. ……………….. Urgency/planned
 4. ……………….. Urgency/planned
(please mention all surgery, and what sort of surgery you had)
 Other, namely …………..
11. Were there any complications during your stay in the hospital?
Please note all complications, and point out if they happened before or after surgery (if 
applicable). Examples of complications (walkthrough with patient):
Confusion, delirium, hallucinations, decubitus, ulcer, wound infections, pneumonia, upper 
airway infection, cystitis, other infections, bladder problems, constipation, cardiovascular 
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events, TIA, stroke, deep venous thrombosis, fall, fractures, gastrointestinal problems, pain, 
deterioration of motor function, increased rigidity, mood problems, pulmonary embolism, 
memory problems, etc. 
 No
 Yes
Complication(s): Before and/or after surgery
a. ……………………. Before/ After/ Before and after/During/ Not applicable
b. ……………………. Before/ After/ Before and after/During/ Not applicable
c. ……………………. Before/ After/ Before and after/During/ Not applicable
d. ……………………. Before/ After/ Before and after/During/ Not applicable
e. ……………………. Before/ After/ Before and after/During/ Not applicable
f. ……………………. Before/ After/ Before and after/During/ Not applicable
12. Was there during this admission an episode of confusion / delirium? 
 No
 Yes. 
If answered yes, please point out the confusion / delirium was yet present before 
hospitalization:
 No, not present before hospitalization
 Yes, present before hospitalization
 Don’t know
13. Did you fall during the hospital stay? 
 No
 Yes, …… times
If you did, please point out if this was before of after surgery (if applicable):
1. ……………………. Before/ After/ Before and after/During/ Not applicable
2. ……………………. Before/ After/ Before and after/During/ Not applicable
3 ……………………. Before/ After/ Before and after/During/ Not applicable
4. ……………………. Before/ After/ Before and after/During/ Not applicable
 Don’t know
 Other, namely ………
14. Was Parkinson’s disease medication distributed according to the same schedule as 
you take your medication at home? (more than one answer possible) 
 Not applicable, no Parkinson’s disease medication
 Yes
 No, the time of medication distribution was not the same 
 No, the kind of Parkinson’s disease medication did not match 
 Don’t know
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 Other answer, namely ………………………….................
15. Was there during one of the admissions an interruption of Parkinson’s disease 
medication? (more than one answer possible)  
 Not applicable, no Parkinson’s disease medication
 No
 Yes, during surgery
 Length of interruption: …… hours/ days
 If more than one surgery, please write down all interruptions.
 Yes, this was on purpose because of ……………………
 Yes, this was not on purpose
 Don’t know
 Other answer, namely ………………………….................
16. Did you have to point out to the personnel that there was a problem with the 
distribution of Parkinson’s disease medication? (more than one answer possible)  
 Not applicable, no Parkinson’s disease medication
 No
 Yes, point out incorrect distribution time
 Yes, point out incorrect Parkinson’s disease medication
 Yes, point out that Parkinson’s disease medication was forgotten
 Don’t know
 Other answer, namely ………………………….................
17. Did you have to point out to the personnel that there was a problem with the 
distribution of Parkinson’s disease medication after a possible surgery? (more than one 
answer possible)  
 Not applicable, no Parkinson’s disease medication
 Not applicable, no surgery
 No, I did have surgery but there was no problem with the medication distribution after 
the surgery.
 Yes, point out incorrect Parkinson’s disease medication
 Yes, point out that Parkinson’s disease medication was forgotten
 Yes, point out that there was incorrect Parkinson’s disease medication 
 Don’t know
 Other answer, namely ………………………….................
18. Was there deterioration of Parkinson’s disease (i.e. decline in motor function) during 
the admission? (more than one answer possible)  
 No, no deterioration 
 Yes, namely …………………(please point out what aspect deteriorated) 
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 Don’t know
 Other answer, namely ……………
19. Did this deterioration start after a possible surgery? (more than one answer possible) 
 Not applicable, no surgery
 Not applicable, no deterioration
 No, deterioration started already before surgery
 Yes, deterioration started after surgery
 Don’t know
 Other answer, namely ………………………….................
20. Did this deterioration start after interruption of Parkinson’s disease medication?
 Not applicable, no Parkinson’s disease medication
 Not applicable, no deterioration
 Not applicable, no surgery
 No
 Yes
 Don’t know
 Other answer, namely …………………
21. Did this deterioration start after transfer to other department? (more than one 
answer possible)  
 Not applicable, no transfer
 Not applicable, no deterioration
 No, deterioration started already before transfer
 Yes, deterioration started after transfer
 Don’t know
 Other answer, namely ………………………….................
22. Was there contact with a Parkinson’s disease nurse specialist or another allied 
healthcare facility during the admission? (for example occupational therapist, speech 
therapist, etc.) 
 No
 Don’t know
 Yes, namely :  
 Parkinson’s disease nurse specialist
   Physical therapy 
   Occupational therapy 
   Speech therapy 
            Psychology 
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    Social worker 
 Another allied healthcare facility, namely:
                 Allied healthcare facility 
                                        ………………….                      
………………….                       
23. Number of days in the hospital:
 ……. Days.
24. Do you return to your original home after discharge? 
 Yes
 No, change of housing situation: 
New housing:  ……………………… Permanent/ Temporary
 Other, namely …………. 
25. Did the investigator contact the nurses or/and doctors about any health related 
problems concerning the patient? 
 No
 Yes,  contact with: nurse / doctor / consultant/ other ……
 concern and advise:  …………………………………………….
 therapeutic consequence:  …………………………………..
28. Comments
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
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ADDITIONAL FILE 4 - QUESTIONNAIRE HOSPITALS
Questionnaire number: ……
Name hospital: ………………….
1. What is your profession?
 Non-academic neurologist
 Academic neurologist
 Non-academic neurologist with special expertise on movement disorders 
 Academic neurologist with special expertise on movement disorders 
 Parkinson’s disease nurse specialist
 Other, namely ..... 
2. In what type of hospital do you work? 
 Non-academic
 Academic
 Other, namely ..... 
3. How many neurologists work in your hospital?
.................................................................................................................................................
4. How many people live in the catchment area of your hospital? 
 <50.000
 50.000-100.000 
 100.000-150.000
 150.000-200.000
 200.000-250.000 
 More, namely …..
5. How many patients do you have in your hospital with the following diagnosis?
- Parkinson’s disease: ….. 
- Parkinsonism: …..
6. Is neurology involved during the hospitalization of patients with Parkinson’s disease 
for another specialty than neurology? 
 No
 Yes, always
 Yes, on specific request of the treating specialist
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 Yes, on specific request of the hospitalized patient
 Other, namely ..... 
7. In your hospital, is there a system to trace admitted Parkinson’s disease patients 
during the hospitalization for another specialty than neurology?
 No
 Yes, the patient is asked to inform the treating specialist
 Yes, through …..
 Other, namely ..... 
8. In your hospital, is there a Parkinson’s disease nurse specialist?
 No (go to question 11)
 Yes 
9. Is the Parkinson’s disease nurse specialist involved during the hospitalization of 
Parkinson’s disease patients for another specialty than neurology? 
 No
 Yes
 Other, namely ..... 
10. Are there, because of the Parkinson’s disease nurse specialist, less admissions of 
Parkinson’s disease patients? 
A for Neurology?
 Yes
 Yes, I think
 Yes, I know
 Other, namely ..... 
B for another specialty?
 Yes
 Yes, I think
 Yes, I know
 Other, namely ..... 
11. Is neurology involved perioperatively for a patient with Parkinson’s disease that is 
going to have surgery? 
 No, never (go to question 12)
 Yes:
ADDITIONAL FILES 139
11
A 
 Yes, always
 Yes, on specific request of the treating specialist
 Other, namely ..... 
B 
 Yes, during all kind of surgeries 
 Yes, during special types of surgeries
        namely ……………………………………………
C 
 Yes, before surgery
 Yes, after surgery
 Yes, during surgery
 Yes, before, during and after surgery
D 
 Yes, only local anesthesia
 Yes, only short general anesthsia
 Yes, only long general anesthesia
 Yes, both short and long anesthesia
 Yes, both local and general anesthsia
E 
 Yes, if the threating specialist expects neurological complications 
 Yes, only if neurological complications have occured
 Yes, also if there are no neurological comlications expected
 Other, namely ..... 
F 
 Yes, only planned surgery
 Yes, only emergency surgery
 Yes, both planned and emergency surgery
12. Is there in your hospital a protocol available with regard to patients with Parkinson’s 
disease having surgery? 
 No (go to question 13)
 Yes 
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A   
If yes, it concerns 
 Advice before surgery 
 Advice during surgery 
 Advice after surgery 
 Advice before, during and after surgery
B   
If yes, is it advice with regard to medication?
 Yes, only medication advice 
 Yes, but also other advice namely …..
 No, other advice namely …..
C   
If yes, could you send it to us?
 Yes 
 No
13. Do you use parenteral dopaminergic medication perioperatively in your hospital for 
Parkinson’s disease patients that use PD medication?
 No, never
 Yes, always
 Yes, only if indicated namely …..
 If yes it concerns ….. 
14. Is there a medication list available in your hospital that shows interaction between 
different types of medication with PD medication?
 No
 Yes, available at neurology
 Yes, available at neurology and on specific request for other specialties
 Yes, available for all specialties 
 Yes, namely …..
15. Could you make an estimation how often per year neurology is involved 
perioperatively for complications with regard to PD patients? 
A 
 No, neurology is never involved
 No, neurology is involved but I don’t now how often 
 Yes, estimated ……… times per year
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 Yes, this is recorded namely …….. times per year
B Which complications do you see? (more	answers	possible)                    Number        
 Pulmonological problems, especially .....                                      
 Cardial problems, especially ….. 
 Gastrointestinal problems, especially …..
 Autonomic nervous system problems, especially  …..
 Motor problems, especially …..
 Cognitive problems, especially …..
 Delirium                                                                                                                             
 Other, namely ..... 
Could you please indicate which complications you see the most by writing down a number 
from 1 to 8 behind te answers of 15B: most frequent one is number 1 and less frequent is 
number 8. 
16. Could you make an estimation how often per year neurology is involved 
postoperatively for complications with regard to PD patients? 
A 
 No, neurology is never involved
 No, neurology is involved but I don’t now how often 
 Yes, estimated ……… times per year
 Yes, this is recorded namely …….. times per year
B Which complications do you see? (more	answers	possible)                    Number        
 Pulmonological problems, especially .....                                      
 Cardial problems, especially ….. 
 Gastrointestinal problems, especially …..
 Autonomic nervous system problems, especially  …..
 Motor problems, especially …..
 Cognitive problems, especially …..
 Delirium                                                                                                                             
 Other, namely ..... 
Could you please indicate which complications you see the most by writing down a number 
from 1 to 8 behind te answers of 16B: most frequent one is number 1 and less frequent is 
number 8. 
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Remarks:
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
.................................................................................................................................................
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op je kan rekenen.
Verder wil ik de beoordelingscommissie bestaande uit Prof. dr. Y. Temel, Prof. dr. T. van Laar, 
Prof. dr. C. Neef, Dr. G. Tissingh en Prof. dr. F. Verhey bedanken. Iedereen heeft het druk en 
tijd is dus kostbaar. Ik waardeer jullie inspanningen. 
Dank ook aan de neurologen die als coauteur of als ‘deelnemer’ inspanningen geleverd 
hebben. Hetzelfde geldt voor de verschillende Parkinsonverpleegkundigen. Dank voor de 
dataverzameling.
Ik dank verder alle patiënten en mantelzorgers die bijgedragen hebben. Jullie zijn de basis 
van dit proefschrift. Jullie waren gelukkig enthousiast ook al was het niet altijd een makkelijke 
periode in jullie leven. Ik hoop dat de bevindingen die dit proefschrift hebben opgeleverd 
jullie in de toekomst van pas zullen komen.
Verder zijn er veel vrienden en familieleden die me indirect bijgestaan hebben. Zonder 
iemand te kort te willen doen toch enkele uitgelicht:
PIP,  bedankt.
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Beste pap, mam en schoonouders Monique en Guido, dank voor jullie ondersteuning! Door 
jullie flexibiliteit heb ik de tijd kunnen vinden om dit proefschrift af te ronden. 
Lieve Rosy, dank voor je steun, geduld en vrije uurtjes die je me gunde om aan dit proefschrift 
te werken. Wie had ooit gedacht toen wij elkaar in Leuven tegenkwamen dat we hier zouden 
staan. Je bent zelfs voor mij helemaal naar het ‘verre’ buitenland verhuisd om hier met mij 
te werken aan onze toekomst. Een mooier cadeau dan Alexis en Thias is er niet. Met jou is 
het nooit saai. Ik hou van je.
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